

STN Columbus

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3	DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18 CA/CAplus patent kind codes updated
NEWS 5	DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27 CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22 CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22 CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29 PHAR reloaded with new search and display fields
NEWS 15	JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26 MEDLINE reloaded with enhancements
NEWS 20	FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16 CASREACT coverage extended
NEWS 26	MAR 20 MARPAT now updated daily
NEWS 27	MAR 22 LWPI reloaded
NEWS 28	MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 29	MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 30	APR 02 JICST-EPLUS removed from database clusters and STN
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 00:28:45 ON 14 APR 2007

=> file ca
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY 0.21	TOTAL SESSION 0.21
-----------------------------	--------------------------

FILE 'CA' ENTERED AT 00:28:55 ON 14 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 17
FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s (bioactive glass or bioinert glass)/ab,bi
    18871 BIOACTIVE/AB
    567261 GLASS/AB
    866 BIOACTIVE GLASS/AB
        ((BIOACTIVE(W) GLASS)/AB)
    24167 BIOACTIVE/BI
    709327 GLASS/BI
    1893 BIOACTIVE GLASS/BI
        ((BIOACTIVE(W) GLASS)/BI)
    281 BIOINERT/AB
    567261 GLASS/AB
    5 BIOINERT GLASS/AB
        ((BIOINERT(W) GLASS)/AB)
    303 BIOINERT/BI
    709327 GLASS/BI
    6 BIOINERT GLASS/BI
        ((BIOINERT(W) GLASS)/BI)
L1      1895 (BIOACTIVE GLASS OR BIOINERT GLASS)/AB,BI

=> s (tissue)/ab,bi
    506814 (TISSUE)/AB
    694908 (TISSUE)/BI
L2      694908 (TISSUE)/AB,BI

=> s l1 and l2
L3      524 L1 AND L2

=> s (silicon dioxide or boron oxide or aluminum oxide or potassium oxide or sodium oxide)/ab
    133409 SILICON/AB
    72552 DIOXIDE/AB
    5380 SILICON DIOXIDE/AB
        ((SILICON(W) DIOXIDE)/AB)
    803630 SILICON/BI
    480604 DIOXIDE/BI
    35468 SILICON DIOXIDE/BI
        ((SILICON(W) DIOXIDE)/BI)
    35110 BORON/AB
    669160 OXIDE/AB
    912 BORON OXIDE/AB
        ((BORON(W) OXIDE)/AB)
    232057 BORON/BI
    1722210 OXIDE/BI
    22357 BORON OXIDE/BI
        ((BORON(W) OXIDE)/BI)
    113961 ALUMINUM/AB
    669160 OXIDE/AB
    6873 ALUMINUM OXIDE/AB
        ((ALUMINUM(W) OXIDE)/AB)
    960380 ALUMINUM/BI
```

1722210 OXIDE/BI
95992 ALUMINUM OXIDE/BI
((ALUMINUM(W)OXIDE)/BI)
96044 POTASSIUM/AB
669160 OXIDE/AB
312 POTASSIUM OXIDE/AB
((POTASSIUM(W)OXIDE)/AB)
623841 POTASSIUM/BI
1722210 OXIDE/BI
19530 POTASSIUM OXIDE/BI
((POTASSIUM(W)OXIDE)/BI)
242667 SODIUM/AB
669160 OXIDE/AB
541 SODIUM OXIDE/AB
((SODIUM(W)OXIDE)/AB)
1094530 SODIUM/BI
1722210 OXIDE/BI
27183 SODIUM OXIDE/BI
((SODIUM(W)OXIDE)/BI)
L4 174432 (SILICON DIOXIDE OR BORON OXIDE OR ALUMINUM OXIDE OR POTASSIUM OXIDE OR SODIUM OXIDE)/AB, BI

=> s 13 and 14
L5 108 L3 AND L4

=> s (Ag or Au or V or Cr or Co or Cu)/ab,bi

303866 AG/AB
314651 AG/BI
173765 AU/AB
179179 AU/BI
976227 V/AB
1076455 V/BI
386843 CR/AB
400886 CR/BI
792219 CO/AB
843874 CO/BI
789373 CU/AB
811795 CU/BI

L6 2988087 (AG OR AU OR V OR CR OR CO OR CU)/AB, BI

=> s 15 and 16
L7 6 L5 AND L6

=> d 1-6

L7 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:425576 CA
TI Effect of polymer processing on the degradation of 45S5 bioglass/poly(lactic acid-*co*-glycolic acid) composite scaffolds for tissue engineering
AU Notinger, Ioan; Blaker, Jonny J.; Maquet, Veronique; Hench, Larry L.; Boccaccini, Aldo R.
CS Department of Materials and Center for Tissue Engineering and Regenerative Medicine, Imperial College London, London, SW7 2BP, UK
SO Asian Journal of Physics (2006), 15(2), 221-230
CODEN: AJPHFU; ISSN: 0971-3093
PB Anita Publications
DT Journal
LA English

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:383290 CA
TI Composites of amorphous calcium phosphate and poly(hydroxybutyrate) and poly(hydroxybutyrate-*co*-hydroxyvalerate) for bone substitution: assessment of the biocompatibility
AU Linhart, Wolfgang; Lehmann, Wolfgang; Siedler, Michael; Peters, Fabian; Schilling, Arndt F.; Schwarz, Karsten; Amling, Michael; Rueger, Johannes Maria; Epple, Matthias

CS Department of Trauma, Hand and Reconstructive Surgery, Hamburg University,
School of Medicine, Hamburg, D-20246, Germany
SO Journal of Materials Science (2006), 41(15), 4806-4813
CODEN: JMTSAS; ISSN: 0022-2461
PB Springer
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN

Full Text
AN 141:248621 CA
TI Bioactivity of SiO₂-CaO-Na₂O glasses modified by silver-surface enrichment
AU Di Nunzio, S.; Verne, E.
CS Department of Material Science and Chemical Engineering, Politecnico di
Torino, Turin, Italy
SO Journal of Applied Biomaterials & Biomechanics (2003), 1(3), 218
CODEN: JABBA7; ISSN: 1722-6899
PB Wichtig Editore
DT Journal
LA English
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN

Full Text
AN 140:395434 CA
TI Influence of physicochemical reactions of **bioactive glass** on the
behavior and activity of human osteoblasts *in vitro*
AU Josset, Y.; Nasrallah, F.; Jallot, E.; Lorenzato, M.; Dufour-mallet, O.;
Balossier, G.; Laurent-maquin, D.
CS INSERM E.R.M. 0203, IFR 53, UFR Odontologie, Reims, 51095, Fr.
SO Journal of Biomedical Materials Research, Part A (2003), 67A(4), 1205-1218
CODEN: JBMRC8
PB John Wiley & Sons, Inc.
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN

Full Text
AN 139:354388 CA
TI Thermodynamics of non-bridging oxygen in silica bio-compatible
glass-ceramics. Mimetic material for the bone **tissue** substitution
AU Koga, N.; Strnad, Z.; Sestak, J.; Strnad, J.
CS Chemistry Laboratory, Department of Science Education, Graduate School of
Education, Hiroshima University, Higashi-Hiroshima, 739-8524, Japan
SO Journal of Thermal Analysis and Calorimetry (2003), 71(3), 927-937
CODEN: JTACF7; ISSN: 1388-6150
PB Kluwer Academic Publishers
DT Journal
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN

Full Text
AN 137:68103 CA
TI Bioactivity of Na₂O.CaO.SiO₂.P₂O₅ modified glasses
AU Barrios de Arenas, Irene; Schattner, Carol; Vasquez, Maritza
CS Electron Microscopy Lab., Department of Materials Technology, I.U.T. -
Region Capital, Caracas, 1040, Venez.
SO Key Engineering Materials (2002), 206-213(Pt. 3, Euro Ceramics VII),
1625-1628
CODEN: KEMAEY; ISSN: 1013-9826
PB Trans Tech Publications Ltd.
DT Journal
LA English
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatall			
COST IN U.S. DOLLARS		SINCE FILE	TOTAL
FULL ESTIMATED COST		ENTRY	SESSION
		89.67	89.88

FILE 'USPATFULL' ENTERED AT 00:31:54 ON 14 APR 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 00:31:54 ON 14 APR 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 00:28:45 ON 14 APR 2007)

FILE 'CA' ENTERED AT 00:28:55 ON 14 APR 2007

L1	1895 S (BIOACTIVE GLASS OR BIOINERT GLASS)/AB,BI
L2	694908 S (TISSUE)/AB,BI
L3	524 S L1 AND L2
L4	174432 S (SILICON DIOXIDE OR BORON OXIDE OR ALUMINUM OXIDE OR POTASSIUM OXIDE OR SODIUM OXIDE)
L5	108 S L3 AND L4
L6	2988087 S (AG OR AU OR V OR CR OR CO OR CU)/AB,BI
L7	6 S L5 AND L6

FILE 'USPATFULL, USPAT2' ENTERED AT 00:31:54 ON 14 APR 2007

=> s (bioactive glass or bioinert glass)
 L8 612 (BIOACTIVE GLASS OR BIOINERT GLASS)

=> s (tissue)
 L9 351006 (TISSUE)

=> s (silicon dioxide or boron oxide or aluminum oxide or potassium oxide or sodium oxide)
 L10 194307 (SILICON DIOXIDE OR BORON OXIDE OR ALUMINUM OXIDE OR POTASSIUM OXIDE OR SODIUM OXIDE)

=> s (Ag or Au or V or Cr or Co or Cu)
 L11 2084571 (AG OR AU OR V OR CR OR CO OR CU)

=> s (bioactive glass or bioinert glass)/clm
 L12 187 (BIOACTIVE GLASS OR BIOINERT GLASS)/CLM

=> s (tissue)/clm
 L13 75611 (TISSUE)/CLM

=> s (silicon dioxide or boron oxide or aluminum oxide or potassium oxide or sodium oxide)/clm
 L14 39506 (SILICON DIOXIDE OR BORON OXIDE OR ALUMINUM OXIDE OR POTASSIUM OXIDE OR SODIUM OXIDE)/CLM

=> s (Ag or Au or V or Cr or Co or Cu)/clm
 L15 382547 (AG OR AU OR V OR CR OR CO OR CU)/CLM

=> s 18 and 19 and 110 and 111
 L16 77 L8 AND L9 AND L10 AND L11

=> s 112 and 113 and 114 and 115
 L17 1 L12 AND L13 AND L14 AND L15

=> d

L17 ANSWER 1 OF 1 USPATFULL on STN
Full Text

AN 2004:196441 USPATFULL

TI Tissue abrasives

IN Zimmer, Jose, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
 Lee, Sean, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
 Rosati, Coni, Encinitas, CA, UNITED STATES

PI US 2004151745 A1 20040805

AI US 2003-696878 A1 20031030 (10)

RLI Continuation-in-part of Ser. No. US 2003-673596, filed on 29 Sep 2003,

PENDING Continuation-in-part of Ser. No. US 2001-818466, filed on 27 Mar 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 816
INCL INCLM: 424/401.000
NCL NCLM: 424/401.000
IC [7]
ICM A61K007-00
IPCI A61K0007-00 [ICM, 7]
IPCR A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61Q0011-00 [I,C*];
A61Q0011-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 116 1-77

L16 ANSWER 1 OF 77 USPATFULL on STN

Full Text
AN 2007:29801 USPATFULL
TI Biomimetic hierarchies using functionalized nanoparticles as building blocks
IN Shastri, Venkatram P, Nashville, TN, UNITED STATES
Chen, I-Wei, Swarthmore, PA, UNITED STATES
Zindarsic, William, Philadelphia, PA, UNITED STATES
PI US 2007026069 A1 20070201
AI US 2004-550923 A1 20040326 (10)
WO 2004-US9192 20040326
20060922 PCT 371 date
PRAI US 2003-458258P 20030328 (60)
DT Utility
FS APPLICATION
LN.CNT 1251
INCL INCLM: 424/486.000
INCLS: 424/489.000; 424/093.700; 977/906.000
NCL NCLM: 424/486.000
NCLS: 424/093.700; 424/489.000; 977/906.000
IC IPCI A61K0035-12 [I,A]; A61K0009-14 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 2 OF 77 USPATFULL on STN

Full Text
AN 2006:274093 USPATFULL
TI Bioactive material for use in stimulating vascularization
IN Day, Richard M., Harrow, UNITED KINGDOM
PA The North West London Hospitals N H S Trust (non-U.S. corporation)
PI US 2006233887 A1 20061019
AI US 2004-545766 A1 20040213 (10)
WO 2004-GB578 20040213
20060522 PCT 371 date
PRAI GB 2003-3371 20030214
GB 2003-23816 20031010
DT Utility
FS APPLICATION
LN.CNT 1444
INCL INCLM: 424/602.000
INCLS: 501/063.000
NCL NCLM: 424/602.000
NCLS: 501/063.000
IC IPCI A61K0033-42 [I,A]; C03C0003-097 [I,A]; C03C0003-076 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 77 USPATFULL on STN

Full Text
AN 2006:250953 USPATFULL
TI Hydraulic cement compositions and methods of making and using the same
IN Lu, Donghui, Vancouver, CANADA
Zhou, Shuxin, Vancouver, CANADA
PI US 2006213395 A1 20060928
AI US 2006-390702 A1 20060327 (11)
PRAI US 2005-664977P 20050325 (60)
DT Utility

FS APPLICATION
LN.CNT 1070
INCL INCLM: 106/035.000
INCLS: 106/691.000; 106/690.000; 106/640.000; 106/736.000; 106/717.000
NCL NCLM: 106/035.000
NCLS: 106/640.000; 106/690.000; 106/691.000; 106/717.000; 106/736.000
IC IPCI C04B0014-48 [I,A]; C04B0014-38 [I,C*]; C04B0028-34 [I,A];
C04B0028-00 [I,C*]; C04B0024-00 [I,A]; C04B0014-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 77 USPATFULL on STN

Full Text

AN 2006:240293 USPATFULL
TI Medical device applications of nanostructured surfaces
IN Dubrow, Robert S., San Carlos, CA, UNITED STATES
Bock, Lawrence A., Encinitas, CA, UNITED STATES
Daniels, R. Hugh, Mountain View, CA, UNITED STATES
Hardev, Veeral D., Redwood City, CA, UNITED STATES
Niu, Chunming, Palo Alto, CA, UNITED STATES
Sahi, Vijendra, Menlo Park, CA, UNITED STATES
PA Nanosys, Inc., Palo Alto, CA, UNITED STATES (U.S. corporation)
PI US 2006204738 A1 20060914
AI US 2006-330722 A1 20060112 (11)
RLI Continuation-in-part of Ser. No. US 2005-90895, filed on 24 Mar 2005,
PENDING Continuation-in-part of Ser. No. US 2004-902700, filed on 29 Jul
2004, PENDING Continuation-in-part of Ser. No. US 2004-828100, filed on
19 Apr 2004, GRANTED, Pat. No. US 7074294 Continuation-in-part of Ser.
No. US 2004-825861, filed on 16 Apr 2004, ABANDONED Continuation-in-part
of Ser. No. US 2003-661381, filed on 12 Sep 2003, GRANTED, Pat. No. US
7056409 Continuation-in-part of Ser. No. US 2004-833944, filed on 27 Apr
2004, PENDING Continuation-in-part of Ser. No. US 2004-840794, filed on
5 May 2004, PENDING Continuation-in-part of Ser. No. US 2004-792402,
filed on 2 Mar 2004, PENDING
PRAI US 2004-549711P 20040302 (60)
US 2003-463766P 20030417 (60)
US 2003-466229P 20030428 (60)
US 2003-468390P 20030506 (60)
US 2003-468606P 20030505 (60)

DT Utility
FS APPLICATION

LN.CNT 5777

INCL INCLM: 428/292.100
NCL NCLM: 428/292.100
IC IPCI D04H0013-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 77 USPATFULL on STN

Full Text

AN 2006:234418 USPATFULL
TI Bioceramic composite coatings and process for making same
IN Troczynski, Tomasz, Vancouver, CANADA
Yang, Quanzu, Vancouver, CANADA
PA The University of British Columbia, Vancouver, CANADA (non-U.S.
corporation)
PI US 2006199876 A1 20060907
AI US 2005-71264 A1 20050304 (11)
DT Utility

FS APPLICATION

LN.CNT 1381

INCL INCLM: 523/115.000
NCL NCLM: 523/115.000
IC IPCI A61K0006-083 [I,A]; A61K0006-02 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 77 USPATFULL on STN

Full Text

AN 2006:60230 USPATFULL
TI IFBMs to promote the specific attachment of target analytes to the
surface of orthopedic implants
IN Beyer, Wayne F. JR., Bahama, NC, UNITED STATES
Hyde-DeRuyscher, Robin, Chapel Hill, NC, UNITED STATES
Hamilton, Paul T., Cary, NC, UNITED STATES

PA Benson, Ray Edward, Durham, NC, UNITED STATES
 PA Affinergy, Inc., Research Triangle Park, NC, UNITED STATES (U.S.
 corporation)
 PI US 2006051395 A1 20060309
 AI US 2005-152974 A1 20050615 (11)
 PRAI US 2004-580019P 20040616 (60)
 US 2005-651338P 20050209 (60)
 US 2005-651747P 20050210 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4530
 INCL INCLM: 424/423.000
 INCLS: 514/002.000
 NCL NCLM: 424/423.000
 NCLS: 514/002.000
 IC IPCI A61K0038-17 [I,A]; A61F0002-00 [I,A]
 IPCR A61K0038-17 [I,A]; A61F0002-00 [I,C]; A61F0002-00 [I,A];
 A61K0038-17 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 77 USPATFULL on STN

Full Text
 AN 2006:15479 USPATFULL
 TI Absorbable implants and methods for their use in hemostasis and in the
 treatment of osseous defects
 IN Kronenthal, Richard L., Fairlawn, NJ, UNITED STATES
 PI US 2006013857 A1 20060119
 AI US 2005-224650 A1 20050912 (11)
 RLI Continuation-in-part of Ser. No. US 2004-941890, filed on 16 Sep 2004,
 PENDING
 PRAI US 2004-628989P 20041118 (60)
 US 2003-504978P 20030923 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1874
 INCL INCLM: 424/426.000
 NCL NCLM: 424/426.000
 IC IPCI A61F0002-00 [I,A]
 IPCR A61F0002-00 [I,A]; A61F0002-00 [I,C]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 77 USPATFULL on STN

Full Text
 AN 2005:254578 USPATFULL
 TI Medical device applications of nanostructured surfaces
 IN Dubrow, Robert S., San Carlos, CA, UNITED STATES
 Sloan, L. Douglas, Santa Rosa, CA, UNITED STATES
 Kronenthal, Richard L., Rutherford, NJ, UNITED STATES
 Alfaro, Arthur A., Colts Neck, NJ, UNITED STATES
 Collier, Matthew D., Los Altos, CA, UNITED STATES
 Rogers, Erica J., Emerald Hills, CA, UNITED STATES
 Gertner, Michael E., Menlo Park, CA, UNITED STATES
 PA Nanosys, Inc., Palo Alto, CA, UNITED STATES, 94304 (U.S. corporation)
 PI US 2005221072 A1 20051006
 AI US 2005-90895 A1 20050324 (11)
 RLI Continuation-in-part of Ser. No. US 2004-902700, filed on 29 Jul 2004,
 PENDING Continuation-in-part of Ser. No. US 2004-828100, filed on 19 Apr
 2004, PENDING Continuation-in-part of Ser. No. US 2003-661381, filed on
 12 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2004-833944,
 filed on 27 Apr 2004, PENDING Continuation-in-part of Ser. No. US
 2004-840794, filed on 5 May 2004, PENDING Continuation-in-part of Ser.
 No. US 2004-792402, filed on 2 Mar 2004, PENDING
 PRAI US 2004-549711P 20040302 (60)
 US 2003-463766P 20030417 (60)
 US 2003-466229P 20030428 (60)
 US 2003-468390P 20030506 (60)
 US 2003-468606P 20030505 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3909
 INCL INCLM: 428/292.100
 NCL NCLM: 428/292.100

IC [7]
ICM D04H003-00
IPCI D04H0003-00 [ICM, 7]
IPCR D04H0003-00 [I,C*]; D04H0003-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 77 USPATFULL on STN

Full Text

AN 2005:203823 USPATFULL
TI Scaffolds with viable tissue
IN Kladakis, Stephanie M., Watertown, MA, UNITED STATES
Dhanaraj, Sridevi, Raritan, NJ, UNITED STATES
Boock, Robert, Braintree, MA, UNITED STATES
PI US 2005177249 A1 20050811
AI US 2004-775034 A1 20040209 (10)
DT Utility
FS APPLICATION
LN.CNT 1262
INCL INCLM: 623/023.740
INCLS: 623/023.760
NCL NCLM: 623/023.740
NCLS: 623/023.760
IC [7]
ICM A61F002-02
IPCI A61F0002-02 [ICM, 7]
IPCR A61L0027-00 [I,A]; A61F0002-00 [I,C*]; A61F0002-00 [I,A];
A61L0027-00 [I,C*]; A61L0027-36 [I,A]; A61L0027-48 [I,A];
A61L0027-56 [I,A]; A61L0027-58 [I,A]

L16 ANSWER 10 OF 77 USPATFULL on STN

Full Text

AN 2005:203819 USPATFULL
TI Absorbable orthopedic implants
IN Leatherbury, Neil C., San Antonio, TX, UNITED STATES
Dinger, Fred B. III, San Antonio, TX, UNITED STATES
Wrana, Jeffrey S., San Antonio, TX, UNITED STATES
Caborn, David, Goshen, KY, UNITED STATES
PI US 2005177245 A1 20050811
AI US 2005-52626 A1 20050207 (11)
PRAI US 2004-542640P 20040205 (60)
DT Utility
FS APPLICATION
LN.CNT 969
INCL INCLM: 623/023.500
INCLS: 623/023.510; 623/017.110
NCL NCLM: 623/023.500
NCLS: 623/017.110; 623/023.510
IC [7]
ICM A61F002-28
ICS A61F002-44
IPCI A61F0002-28 [ICM, 7]; A61F0002-44 [ICS, 7]
IPCR A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-44 [I,C*];
A61F0002-44 [I,A]

L16 ANSWER 11 OF 77 USPATFULL on STN

Full Text

AN 2005:157834 USPATFULL
TI Methods and compositions for tissue repair
IN Betz, Oliver B., Boston, MA, UNITED STATES
Betz, Volker M., Boston, MA, UNITED STATES
Evans, Christopher H., Cohasset, MA, UNITED STATES
PI US 2005136042 A1 20050623
AI US 2004-917265 A1 20040811 (10)
PRAI US 2003-494484P 20030812 (60)
DT Utility
FS APPLICATION
LN.CNT 3417
INCL INCLM: 424/093.210
INCLS: 435/455.000; 435/456.000; 435/366.000
NCL NCLM: 424/093.210
NCLS: 435/366.000; 435/455.000; 435/456.000
IC [7]

ICM A61K048-00
ICS C12N005-08; C12N015-86
IPCI A61K0048-00 [ICM, 7]; C12N0005-08 [ICS, 7]; C12N0015-86 [ICS, 7]
IPCR A61K0048-00 [I,C*]; A61K0048-00 [I,A]; C12N0005-08 [I,C*];
C12N0005-08 [I,A]; C12N0015-86 [I,C*]; C12N0015-86 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 77 USPATFULL on STN

Full Text

AN 2005:145336 USPATFULL
TI Viable tissue repair implants and methods of use
IN Harmon, Alexander M., Clinton, NJ, UNITED STATES
Kladakis, Stephanie M., Watertown, MA, UNITED STATES
Hwang, Julia, Wayland, MA, UNITED STATES
PI US 2005125077 A1 20050609
AI US 2003-729046 A1 20031205 (10)
DT Utility
FS APPLICATION
LN.CNT 1723
INCL INCLM: 623/023.720
INCLS: 435/401.000
NCL NCLM: 623/023.720
NCLS: 435/401.000
IC [7]
ICM A61F002-02
ICS C12N005-08
IPCI A61F0002-02 [ICM, 7]; C12N0005-08 [ICS, 7]
IPCR A61L0027-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61L0027-00 [I,C*];
A61L0027-38 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 77 USPATFULL on STN

Full Text

AN 2005:137585 USPATFULL
TI Methods and compositions for regenerating connective tissue
IN Hill, Ronald Stewart, Greenville, NC, UNITED STATES
Klann, Richard Chris, Washington, NC, UNITED STATES
Lamberti, Francis V., Greenville, NC, UNITED STATES
PA Encelle, Inc. (U.S. corporation)
PI US 2005118230 A1 20050602
AI US 2004-971544 A1 20041022 (10)
PRAI US 2003-513392P 20031022 (60)
DT Utility
FS APPLICATION
LN.CNT 2047
INCL INCLM: 424/426.000
INCLS: 514/008.000; 514/021.000; 424/093.700
NCL NCLM: 424/426.000
NCLS: 424/093.700; 514/008.000; 514/021.000
IC [7]
ICM A61K038-38
ICS A61K045-00
IPCI A61K0038-38 [ICM, 7]; A61K0045-00 [ICS, 7]
IPCR A61K0038-18 [I,C*]; A61K0038-18 [I,A]; A61K0038-19 [I,C*];
A61K0038-19 [I,A]; A61K0038-30 [I,C*]; A61K0038-30 [I,A];
A61K0038-38 [I,C*]; A61K0038-38 [I,A]; A61K0038-39 [I,C*];
A61K0038-39 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
A61L0027-00 [I,C*]; A61L0027-48 [I,A]; A61L0027-52 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 77 USPATFULL on STN

Full Text

AN 2005:75913 USPATFULL
TI Absorbable implants and methods for their use in hemostasis and in the
treatment of osseous defects
IN Kronenthal, Richard L., Fair Lawn, NJ, UNITED STATES
PI US 2005065214 A1 20050324
AI US 2004-941890 A1 20040916 (10)
PRAI US 2003-504978P 20030923 (60)
DT Utility
FS APPLICATION

LN.CNT 2741
INCL INCLM: 514/557.000
INCLS: 424/464.000
NCL NCLM: 514/557.000
NCLS: 424/464.000
IC [7]
ICM A61K009-20
ICS A61K031-19
IPCI A61K009-20 [ICM,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
IPCR A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61L0024-00 [I,C*];
A61L0024-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 77 USPATFULL on STN

Full Text

AN 2005:59069 USPATFULL
TI Osteogenic implants derived from bone
IN Boyce, Todd M., Aberdeen, NJ, United States
Kaes, David, Toms River, NJ, United States
Scarborough, Nelson L., Ocean, NJ, United States
PA Osteotech, Inc., Eatontown, NJ, United States (U.S. corporation)
PI US 6863694 B1 20050308
AI US 2000-610026 20000703 (9)
DT Utility
FS GRANTED
LN.CNT 1330
INCL INCLM: 623/023.630
INCLS: 623/023.610
NCL NCLM: 623/023.630
NCLS: 623/023.610
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM,7]
IPCR A61L0027-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A];
A61L0027-00 [I,C*]; A61L0027-36 [I,A]
EXF 623/23.61; 623/23.63; 523/113; 523/115; 435/372

L16 ANSWER 16 OF 77 USPATFULL on STN

Full Text

AN 2005:44785 USPATFULL
TI Method and apparatus for resurfacing an articular surface
IN Binette, Francois, Weymouth, MA, UNITED STATES
Lu, Ed Yiling, Chestnut Hill, MA, UNITED STATES
PI US 2005038520 A1 20050217
AI US 2003-638562 A1 20030811 (10)
DT Utility
FS APPLICATION
LN.CNT 1616
INCL INCLM: 623/018.110
INCLS: 623/023.610; 623/908.000
NCL NCLM: 623/018.110
NCLS: 623/023.610; 623/908.000
IC [7]
ICM A61F002-08
IPCI A61F0002-08 [ICM,7]
IPCR A61L0027-00 [I,A]; A61B0017-00 [N,C*]; A61B0017-00 [N,A];
A61B0017-064 [N,C*]; A61B0017-064 [N,A]; A61F0002-00 [N,C*];
A61F0002-00 [N,A]; A61F0002-02 [N,C*]; A61F0002-02 [N,A];
A61F0002-30 [I,C*]; A61F0002-30 [I,A]; A61F0002-38 [N,C*];
A61F0002-38 [N,A]; A61L0027-00 [I,C*]; A61L0027-36 [I,A];
A61L0027-38 [I,A]

L16 ANSWER 17 OF 77 USPATFULL on STN

Full Text

AN 2005:44763 USPATFULL
TI Medical device applications of nanostructured surfaces
IN Dubrow, Robert S., San Carlos, CA, UNITED STATES
Sloan, L. Douglas, Santa Rosa, CA, UNITED STATES
Kronenthal, Richard L., Fair Lawn, NJ, UNITED STATES
Alfaro, Arthur A., Cots Neck, NJ, UNITED STATES
Collier, Matthew D., Los Altos, CA, UNITED STATES
Rogers, Erica J., Emerald Hills, CA, UNITED STATES

PA Gertner, Michael E., Menlo Park, CA, UNITED STATES
 PA Nanosys, Inc., Palo Alto, CA, UNITED STATES, 94304 (U.S. corporation)
 PI US 2005038498 A1 20050217
 AI US 2004-902700 A1 20040729 (10)
 RLI Continuation-in-part of Ser. No. US 2004-828100, filed on 19 Apr 2004,
 PENDING Continuation-in-part of Ser. No. US 2003-661381, filed on 12 Sep
 2003, PENDING Continuation-in-part of Ser. No. US 2004-833944, filed on
 27 Apr 2004, PENDING Continuation-in-part of Ser. No. US 2004-840794,
 filed on 5 May 2004, PENDING Continuation-in-part of Ser. No. US
 2004-792402, filed on 2 Mar 2004, PENDING
 PRAI US 2004-549711P 20040302 (60)
 US 2003-463766P 20030417 (60)
 US 2003-466229P 20030428 (60)
 US 2003-468390P 20030506 (60)
 US 2003-468606P 20030505 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3602
 INCL INCLM: 623/001.150
 INCLS: 606/153.000
 NCL NCLM: 623/001.150
 NCLS: 606/153.000
 IC [7]
 ICM A61F002-06
 ICS A61B017-08
 IPCI A61F0002-06 [ICM,7]; A61B0017-08 [ICS,7]; A61B0017-03 [ICS,7,C*]
 IPCR A61B0017-03 [I,C*]; A61B0017-08 [I,A]; A61F0002-06 [I,C*];
 A61F0002-06 [I,A]

L16 ANSWER 18 OF 77 USPATFULL on STN

Full Text

AN 2005:37028 USPATFULL
 TI Antimicrobial, water-insoluble silicate glass powder and mixture of
 glass powders
 IN Beier, Wolfram, Essenheim, GERMANY, FEDERAL REPUBLIC OF
 Fechner, Jorg Hinrich, Mainz, GERMANY, FEDERAL REPUBLIC OF
 Schnell, Rupert, Worms, GERMANY, FEDERAL REPUBLIC OF
 Zimmer, Jose, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
 PA Schott Glas (non-U.S. corporation)
 PI US 2005031703 A1 20050210
 AI US 2004-897689 A1 20040723 (10)
 RLI Continuation of Ser. No. WO 2003-EP559, filed on 21 Jan 2003, UNKNOWN
 PRAI DE 2002-10202630 20020124
 DT Utility
 FS APPLICATION
 LN.CNT 414
 INCL INCLM: 424/601.000
 INCLS: 501/077.000; 424/618.000
 NCL NCLM: 424/601.000
 NCLS: 424/618.000; 501/077.000
 IC [7]
 ICM A61K033-42
 ICS C03C003-118; C03C003-064; A61K033-38
 IPCI A61K0033-42 [ICM,7]; C03C0003-118 [ICS,7]; C03C0003-076
 [ICS,7,C*]; C03C0003-064 [ICS,7]; C03C0003-062 [ICS,7,C*];
 A61K0033-38 [ICS,7]
 IPCR A61L0029-00 [I,C*]; A61L0029-00 [I,A]; A01N0059-16 [I,C*];
 A01N0059-16 [I,A]; C03C0003-062 [I,C*]; C03C0003-062 [I,A];
 C03C0003-064 [I,A]; C03C0003-066 [I,A]; C03C0003-076 [I,C*];
 C03C0003-078 [I,A]; C03C0003-085 [I,A]; C03C0003-087 [I,A];
 C03C0003-089 [I,A]; C03C0003-091 [I,A]; C03C0003-093 [I,A];
 C03C0003-097 [I,A]; C03C0004-00 [I,C*]; C03C0004-00 [I,A];
 C03C0008-00 [I,C*]; C03C0008-22 [I,A]; C03C0012-00 [I,C*];
 C03C0012-00 [I,A]; C09D0005-14 [I,C*]; C09D0005-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 77 USPATFULL on STN

Full Text

AN 2004:336264 USPATFULL
 TI Scaffold for connective tissue repair
 IN Hwang, Julia, Wayland, MA, UNITED STATES
 Hammer, Joseph, Bridgewater, NJ, UNITED STATES

Schwartz, Herb, Fort Wayne, IN, UNITED STATES
 Malaviya, Prasanna, Fort Wayne, IN, UNITED STATES
 PI US 2004267362 A1 20041230
 AI US 2003-610362 A1 20030630 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 1532
 INCL INCLM: 623/013.150
 INCLS: 623/013.170; 623/013.190; 623/013.180
 NCL NCLM: 623/013.150
 NCLS: 623/013.170; 623/013.180; 623/013.190
 IC [7]
 ICM A61F002-08
 IPCI A61F0002-08 [ICM, 7]
 IPCR A61L0027-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
 A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-36 [I,A];
 A61L0027-56 [I,A]

L16 ANSWER 20 OF 77 USPATFULL on STN

Full Text
 AN 2004:336166 USPATFULL
 TI Porous resorbable graft fixation pin
 IN May, Thomas, Wrentham, MA, UNITED STATES
 PA ETHICON, INC., Somerville, NJ (U.S. corporation)
 PI US 2004267263 A1 20041230
 AI US 2003-602797 A1 20030624 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 731
 INCL INCLM: 606/072.000
 NCL NCLM: 606/072.000
 IC [7]
 ICM A61B017-56
 IPCI A61B0017-56 [ICM, 7]
 IPCR A61B0017-56 [I,C*]; A61B0017-56 [I,A]; A61B0017-00 [N,C*];
 A61B0017-00 [N,A]; A61B0017-68 [I,C*]; A61B0017-84 [I,A];
 A61B0017-86 [I,A]

L16 ANSWER 21 OF 77 USPATFULL on STN

Full Text
 AN 2004:315338 USPATFULL
 TI Method of manufacturing dental restorations
 IN Jia, Weitao, Wallingford, CT, UNITED STATES
 Jin, Shuhua, Wallingford, CT, UNITED STATES
 PI US 2004249015 A1 20041209
 AI US 2004-862177 A1 20040604 (10)
 RLI Division of Ser. No. US 2001-5298, filed on 5 Dec 2001, GRANTED, Pat.
 No. US 6787584 Continuation-in-part of Ser. No. US 2000-638206, filed on
 11 Aug 2000, GRANTED, Pat. No. US 6455608
 PRAI US 2000-251408P 20001205 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 747
 INCL INCLM: 523/115.000
 NCL NCLM: 523/115.000
 IC [7]
 ICM A61F002-00
 IPCI A61F0002-00 [ICM, 7]
 IPCR A61K0006-00 [I,C*]; A61K0006-00 [I,A]; A61K0006-02 [I,C*];
 A61K0006-083 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A];
 A61L0027-00 [I,C*]; A61L0027-44 [I,A]; A61L0027-46 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 22 OF 77 USPATFULL on STN

Full Text
 AN 2004:308455 USPATFULL
 TI Method and system for manufacturing biomedical articles, such as using
 biomedically compatible infiltrant metal alloys in porous matrices
 IN Materna, Peter A., Metuchen, NJ, UNITED STATES
 PA Therics, Inc., Princeton, NJ (U.S. corporation)
 PI US 2004243133 A1 20041202
 AI US 2004-794802 A1 20040305 (10)

PRAI US 2003-452795P 20030305 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1234
 INCL INCLM: 606/076.000
 INCLS: 420/417.000; 420/422.000; 420/425.000; 623/023.550; 623/023.500
 NCL NCLM: 606/076.000
 NCLS: 420/417.000; 420/422.000; 420/425.000; 623/023.500; 623/023.550
 IC [7]
 ICM A61F002-28
 ICS C22C014-00
 IPCI A61F0002-28 [ICM, 7]; C22C0014-00 [ICS, 7]
 IPCR A61L0027-00 [I,C*]; A61L0027-04 [I,A]; A61L0027-42 [I,A];
 C04B0041-45 [I,C*]; C04B0041-51 [I,A]; C04B0041-88 [I,C*];
 C04B0041-88 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 77 USPATFULL on STN

Full Text

AN 2004:293217 USPATFULL
 TI In-situ formed intervertebral fusion device and method
 IN DiMauro, Thomas M., Southboro, MA, UNITED STATES
 Slivka, Michael Andrew, Taunton, MA, UNITED STATES
 Malone, John Daniel, Cumberland, RI, UNITED STATES
 Moore, Bradley Thomas, Barrington, RI, UNITED STATES
 Serhan, Hassan, South Easton, MA, UNITED STATES
 Kadiyala, Sudhakar, South Easton, MA, UNITED STATES
 Bartish, Charles M., JR., Providence, RI, UNITED STATES
 Woodrow, Hal Brent, Princeton, NJ, UNITED STATES
 Rohr, William L., Palm Beach Gardens, FL, UNITED STATES
 Kelly, James Edward, North Easton, MA, UNITED STATES
 Cooper, Kevin, Flemington, NJ, UNITED STATES
 Aquino, Lauren, Boston, MA, UNITED STATES
 PA DePuy Spine, Inc., Raynham, MA (U.S. corporation)
 PI US 2004230309 A1 20041118
 AI US 2004-778684 A1 20040213 (10)
 PRAI US 2003-448221P 20030214 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5024
 INCL INCLM: 623/017.120
 INCLS: 623/017.110
 NCL NCLM: 623/017.120
 NCLS: 623/017.110
 IC [7]
 ICM A61F002-44
 ICS A61F002-46
 IPCI A61F0002-44 [ICM, 7]; A61F0002-46 [ICS, 7]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-02 [N,C*];
 A61F0002-02 [N,A]; A61F0002-28 [N,C*]; A61F0002-28 [N,A];
 A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61F0002-44 [I,C*];
 A61F0002-44 [I,A]; A61F0002-46 [I,C*]; A61F0002-46 [I,A];
 A61L0027-00 [I,C*]; A61L0027-18 [I,A]; A61L0027-50 [I,A];
 A61L0027-54 [I,A]

L16 ANSWER 24 OF 77 USPATFULL on STN

Full Text

AN 2004:291824 USPATFULL
 TI Anti-inflammatory and antimicrobial uses for bioactive glass
 compositions
 IN Greenspan, David C., Gainesville, FL, UNITED STATES
 West, Jon K., Gainesville, FL, UNITED STATES
 Lee, Sean, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
 Meyers, James L., Gainesville, FL, UNITED STATES
 Diamond, Mason, Gainesville, FL, UNITED STATES
 PI US 2004228905 A1 20041118
 AI US 2004-865636 A1 20040610 (10)
 RLI Continuation of Ser. No. US 2000-560046, filed on 27 Apr 2000, GRANTED,
 Pat. No. US 6756060 Continuation-in-part of Ser. No. US 1998-164293,
 filed on 1 Oct 1998, GRANTED, Pat. No. US 6428800 Continuation of Ser.
 No. US 1996-715911, filed on 19 Sep 1996, GRANTED, Pat. No. US 5834008
 Continuation of Ser. No. US 1999-392516, filed on 9 Sep 1999, ABANDONED

PRAI US 1998-99725P 19980910 (60)
DT Utility
FS APPLICATION
LN.CNT 1072
INCL INCLM: 424/445.000
INCLS: 424/617.000; 514/035.000; 514/152.000
NCL NCLM: 424/445.000
NCLS: 424/617.000; 514/035.000; 514/152.000
IC [7]
ICM A61K033-24
ICS A61K009-14; A61K031-65
IPCI A61K0033-24 [ICM, 7]; A61K0009-14 [ICS, 7]; A61K0031-65 [ICS, 7]
IPCR A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]; A61L0015-16 [I,C*]; A61L0015-18 [I,A];
A61L0015-44 [I,A]; A61L0015-46 [I,A]; A61Q0001-02 [I,C*];
A61Q0001-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A];
A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; C03C0004-00 [I,C*];
C03C0004-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 77 USPATFULL on STN

Full Text

AN 2004:215066 USPATFULL
TI Bioactive tissue abrasives
IN Rosati, Coni, Encinitas, CA, UNITED STATES
Lee, Sean, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
Zimmer, Jose, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2004166172 A1 20040826
AI US 2003-673596 A1 20030929 (10)
RLI Continuation-in-part of Ser. No. US 2001-818466, filed on 27 Mar 2001,
PENDING
DT Utility
FS APPLICATION
LN.CNT 568
INCL INCLM: 424/601.000
INCLS: 501/063.000
NCL NCLM: 424/601.000
NCLS: 501/063.000
IC [7]
ICM A61K033-42
ICS C03C003-097
IPCI A61K0033-42 [ICM, 7]; C03C0003-097 [ICS, 7]; C03C0003-076
[ICS, 7,C*]
IPCR A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61Q0011-00 [I,C*];
A61Q0011-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 77 USPATFULL on STN

Full Text

AN 2004:204438 USPATFULL
TI Surface treated metallic implant and blasting material
IN Muller, Wolf-Dieter, Berlin, GERMANY, FEDERAL REPUBLIC OF
Berger, Georg, Zepernick, GERMANY, FEDERAL REPUBLIC OF
PI US 2004158330 A1 20040812
AI US 2003-480918 A1 20031215 (10)
WO 2002-DE2229 20020614
PRAI DE 2001-10129843 20010615
DT Utility
FS APPLICATION
LN.CNT 474
INCL INCLM: 623/023.570
INCLS: 623/023.560; 501/010.000
NCL NCLM: 623/023.570
NCLS: 501/010.000; 623/023.560
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM, 7]
IPCR A61L0027-00 [I,C*]; A61L0027-30 [I,A]; A61L0027-32 [I,A];
A61L0027-42 [I,A]; B24C0001-00 [I,C*]; B24C0001-06 [I,A];
B24C0011-00 [I,C*]; B24C0011-00 [I,A]; C03C0004-00 [I,C*];
C03C0004-00 [I,A]; C03C0010-00 [I,C*]; C03C0010-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 77 USPATFULL on STN

Full Text

AN 2004:196441 USPATFULL
TI **Tissue abrasives**
IN Zimmer, Jose, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Lee, Sean, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
Rosati, Coni, Encinitas, CA, UNITED STATES
PI US 2004151745 A1 20040805
AI US 2003-696878 A1 20031030 (10)
RLI Continuation-in-part of Ser. No. US 2003-673596, filed on 29 Sep 2003,
PENDING Continuation-in-part of Ser. No. US 2001-818466, filed on 27 Mar
2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 816
INCL INCLM: 424/401.000
NCL NCLM: 424/401.000
IC [7]
ICM A61K007-00
IPCI A61K0007-00 [ICM, 7]
IPCR A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61Q0011-00 [I,C*];
A61Q0011-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 77 USPATFULL on STN

Full Text

AN 2004:161242 USPATFULL
TI **Anti-inflammatory and antimicrobial uses for bioactive glass compositions**
IN Greenspan, David C., Gainesville, FL, United States
West, Jon K., Gainesville, FL, United States
Lee, Sean, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
Meyers, James L., Gainesville, FL, United States
Diamond, Mason, Gainesville, FL, United States
PA USBiomaterials Corp., Alachua, FL, United States (U.S. corporation)
PI US 6756060 B1 20040629
AI US 2000-560046 20000427 (9)
RLI Continuation-in-part of Ser. No. US 1998-164293, filed on 1 Oct 1998,
now patented, Pat. No. US 6428800 Continuation of Ser. No. US
1996-715911, filed on 19 Sep 1996, now patented, Pat. No. US 5834008
Continuation of Ser. No. US 1999-392516, filed on 9 Sep 1999, now
abandoned
PRAI US 1998-99725P 19980910 (60)
DT Utility
FS GRANTED
LN.CNT 1100
INCL INCLM: 424/489.000
INCLS: 424/400.000; 424/401.000; 424/402.000; 424/404.000; 424/405.000;
424/443.000; 424/445.000; 424/446.000; 424/447.000; 424/484.000;
424/601.000; 424/602.000; 424/606.000; 424/657.000; 424/660.000;
424/675.000; 424/688.000; 424/692.000; 424/722.000; 424/724.000;
424/DIG.013; 514/829.000; 514/830.000; 514/831.000; 514/859.000;
514/861.000; 514/862.000; 514/863.000; 514/864.000; 514/886.000;
514/887.000; 514/951.000; 514/965.000
NCL NCLM: 424/489.000
NCLS: 424/400.000; 424/401.000; 424/402.000; 424/404.000; 424/405.000;
424/443.000; 424/445.000; 424/446.000; 424/447.000; 424/484.000;
424/601.000; 424/602.000; 424/606.000; 424/657.000; 424/660.000;
424/675.000; 424/688.000; 424/692.000; 424/722.000; 424/724.000;
424/DIG.013; 514/829.000; 514/830.000; 514/831.000; 514/859.000;
514/861.000; 514/862.000; 514/863.000; 514/864.000; 514/886.000;
514/887.000; 514/951.000; 514/965.000
IC [7]
ICM A61K009-14
ICS A61K033-00; A61K033-06; A61K033-08; A61K033-16
IPCI A61K0009-14 [ICM, 7]; A61K0033-00 [ICS, 7]; A61K0033-06 [ICS, 7];
A61K0033-08 [ICS, 7]; A61K0033-06 [ICS, 7,C*]; A61K0033-16 [ICS, 7]
IPCR A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0045-00 [I,C*];
A61K0045-06 [I,A]; A61L0015-16 [I,C*]; A61L0015-18 [I,A];
A61L0015-44 [I,A]; A61L0015-46 [I,A]; A61Q0001-02 [I,C*];
A61Q0001-02 [I,A]; A61Q0005-00 [I,C*]; A61Q0005-00 [I,A];

A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; C03C0004-00 [I,C*];
C03C0004-00 [I,A]

EXF 424/400; 424/401; 424/484; 424/489; 424/601-602; 424/606; 424/657;
424/660; 424/675; 424/688; 424/692; 424/722; 424/724; 424/402; 424/404;
424/405; 424/443; 424/445; 424/446; 424/447; 424/DIG.13; 623/11.11;
514/829-831; 514/859; 514/861; 514/862; 514/863; 514/864; 514/886;
514/887; 514/951; 514/965; 602/41-45; 604/304; 604/305; 604/309;
604/310; 604/311; 604/903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 29 OF 77 USPATFULL on STN

Full Text

AN 2004:102220 USPATFULL
TI Biocompatible scaffolds with tissue fragments
IN Binette, Francois, Weymouth, MA, UNITED STATES
Hwang, Julia, Wayland, MA, UNITED STATES
Dhanaraj, Sridevi, Raritan, NJ, UNITED STATES
Gosiewska, Anna, Skilman, NJ, UNITED STATES
PI US 2004078090 A1 20040422
AI US 2003-374772 A1 20030225 (10)
PRAI US 2002-420093P 20021018 (60)
US 2002-419539P 20021018 (60)
DT Utility
FS APPLICATION
LN.CNT 2319
INCL INCLM: 623/023.760
INCLS: 435/395.000
NCL NCLM: 623/023.760
NCLS: 435/395.000
IC [7]
ICM A61F002-02
IPCI A61F0002-02 [ICM, 7]
IPCR A61L0027-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
A61F0002-10 [I,C*]; A61F0002-10 [I,A]; A61F0002-28 [I,C*];
A61F0002-28 [I,A]; A61F0002-30 [I,C*]; A61F0002-30 [I,A];
A61L0027-00 [I,C*]; A61L0027-36 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 30 OF 77 USPATFULL on STN

Full Text

AN 2004:102207 USPATFULL
TI Biocompatible scaffold for ligament or tendon repair
IN Binette, Francois, Weymouth, MA, UNITED STATES
Hwang, Julia, Watertown, MA, UNITED STATES
Zimmerman, Mark, East Brunswick, NJ, UNITED STATES
Melican, Mora Carolynne, Bridgewater, NJ, UNITED STATES
PI US 2004078077 A1 20040422
AI US 2003-374754 A1 20030225 (10)
PRAI US 2002-420093P 20021018 (60)
US 2002-419539P 20021018 (60)
DT Utility
FS APPLICATION
LN.CNT 1934
INCL INCLM: 623/013.170
NCL NCLM: 623/013.170
IC [7]
ICM A61F002-08
IPCI A61F0002-08 [ICM, 7]
IPCR A61L0027-00 [I,A]; A61F0002-08 [I,C*]; A61F0002-08 [I,A];
A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61L0027-00 [I,C*];
A61L0027-36 [I,A]

L16 ANSWER 31 OF 77 USPATFULL on STN

Full Text

AN 2004:71143 USPATFULL
TI Biodegradable composites
IN Corden, Thomas Joseph, Nottingham, UNITED KINGDOM
Downes, Sandra, Nottingham, UNITED KINGDOM
Fisher, Sheila Eunice, Nottingham, UNITED KINGDOM
Jones, Ivor Arthur, Nottingham, UNITED KINGDOM
Rudd, Christopher Douglas, Nottingham, UNITED KINGDOM
PA BTG International Limited (non-U.S. corporation)

PI US 2004054372 A1 20040318
 AI US 2003-625524 A1 20030724 (10)
 RLI Division of Ser. No. US 2000-506363, filed on 18 Feb 2000, ABANDONED
 Continuation of Ser. No. WO 1998-GB2399, filed on 19 Aug 1998, UNKNOWN
 PRAI GB 1997-17433 19970819
 DT Utility
 FS APPLICATION
 LN.CNT 1089
 INCL INCLM: 606/077.000
 INCLS: 435/398.000
 NCL NCLM: 606/077.000
 NCLS: 435/398.000
 IC [7]
 ICM A61F002-28
 ICS A61F002-02
 IPCI A61F0002-28 [ICM, 7]; A61F0002-02 [ICS, 7]
 IPCR A61L0027-00 [I,C*]; A61L0027-44 [I,A]; A61L0027-48 [I,A];
 A61L0027-58 [I,A]; B29C0033-38 [I,C*]; B29C0033-38 [I,A];
 B29C0070-04 [I,C*]; B29C0070-48 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 32 OF 77 USPATFULL on STN

Full Text

AN 2004:41271 USPATFULL
 TI Bone repair composite material
 IN Healy, David Michael, Ayr, UNITED KINGDOM
 Gilchrist, Thomas, Ayr, UNITED KINGDOM
 PA Fite Holdings Limited, Glasgow, UNITED KINGDOM (non-U.S. corporation)
 PI US 6692532 B1 20040217
 WO 2000016819 20000330
 AI US 2001-787384 20010518 (9)
 WO 1999-GB3077 19990915
 PRAI GB 1998-20369 19980919
 DT Utility
 FS GRANTED
 LN.CNT 805
 INCL INCLM: 623/023.510
 INCLS: 623/023.560; 623/023.610; 623/023.630
 NCL NCLM: 623/023.510
 NCLS: 623/023.560; 623/023.610; 623/023.630
 IC [7]
 ICM A61F002-28
 IPCI A61F0002-28 [ICM, 7]
 IPCR A61L0027-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-00 [I,A];
 A61L0027-00 [I,C*]; A61L0027-10 [I,A]; A61L0027-36 [I,A];
 A61L0027-42 [I,A]
 EXF 623/23.51; 623/23.61; 623/23.71; 623/23.73; 623/11.11; 623/16.11;
 623/23.63; 623/23.56; 623/23.62; 623/17.11; 523/115; 523/116

L16 ANSWER 33 OF 77 USPATFULL on STN

Full Text

AN 2004:13078 USPATFULL
 TI Use of bioactive glass compositions to stimulate osteoblast production
 IN Hench, Larry L, London, UNITED KINGDOM
 Polak, Julia M, London, UNITED KINGDOM
 Buttery, Lee D.k., London, UNITED KINGDOM
 Xynos, Ioannis D, Nafplion, GREECE
 Maroorthynaden, Jason, London, UNITED KINGDOM
 PI US 2004009598 A1 20040115
 AI US 2003-332731 A1 20030707 (10)
 WO 2001-US21801 20010711
 DT Utility
 FS APPLICATION
 LN.CNT 1301
 INCL INCLM: 435/375.000
 INCLS: 435/395.000
 NCL NCLM: 435/375.000
 NCLS: 435/395.000
 IC [7]
 ICM C12N005-00
 ICS C12N005-02
 IPCI C12N0005-00 [ICM, 7]; C12N0005-02 [ICS, 7]

IPCR C12N0005-02 [I,C*]; C12N0005-02 [I,A]; C12N0005-06 [I,C*];
C12N0005-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 34 OF 77 USPATFULL on STN

Full Text

AN 2004:2747 USPATFULL
TI Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
IN King, Richard S., Warsaw, IN, UNITED STATES
Smith, Todd S., Fort Wayne, IN, UNITED STATES
PI US 2004002770 A1 20040101
AI US 2003-449058 A1 20030602 (10)
PRAI US 2002-392488P 20020628 (60)
DT Utility
FS APPLICATION
LN.CNT 856
INCL INCLM: 623/023.510
INCLS: 424/425.000; 264/273.000
NCL NCLM: 623/023.510
NCLS: 264/273.000; 424/425.000
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM,7]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-02 [N,C*];
A61F0002-02 [N,A]; A61F0002-28 [N,C*]; A61F0002-28 [N,A];
A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61L0027-00 [I,C*];
A61L0027-42 [I,A]; A61L0027-46 [I,A]; A61L0027-54 [I,A];
A61L0027-56 [I,A]; A61L0027-58 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 77 USPATFULL on STN

Full Text

AN 2003:330531 USPATFULL
TI Cross-linked bioactive hydrogel matrices
IN Lamberti, Francis V., Greenville, NC, UNITED STATES
Klann, Richard Chris, Washington, NC, UNITED STATES
Hill, Ronald Stewart, Greenville, NC, UNITED STATES
PA Encelle, Inc. (U.S. corporation)
PI US 2003232746 A1 20031218
AI US 2003-372643 A1 20030221 (10)
PRAI US 2002-358625P 20020221 (60)
DT Utility
FS APPLICATION
LN.CNT 1495
INCL INCLM: 514/002.000
INCLS: 514/054.000; 514/055.000; 514/056.000; 514/057.000; 514/060.000;
514/059.000; 424/488.000; 514/561.000
NCL NCLM: 514/002.000
NCLS: 424/488.000; 514/054.000; 514/055.000; 514/056.000; 514/057.000;
514/059.000; 514/060.000; 514/561.000
IC [7]
ICM A61K038-17
ICS A61K031-737; A61K031-728; A61K031-727; A61K031-717; A61K031-718;
A61K031-721; A61K031-722; A61K031-195; A61K009-14; A61K031-198
IPCI A61K0038-17 [ICM,7]; A61K0031-737 [ICS,7]; A61K0031-728 [ICS,7];
A61K0031-727 [ICS,7]; A61K0031-726 [ICS,7,C*]; A61K0031-717
[ICS,7]; A61K0031-718 [ICS,7]; A61K0031-721 [ICS,7]; A61K0031-722
[ICS,7]; A61K0031-716 [ICS,7,C*]; A61K0031-195 [ICS,7];
A61K0009-14 [ICS,7]; A61K0031-198 [ICS,7]; A61K0031-185
[ICS,7,C*]
IPCR A61L0027-00 [I,C*]; A61L0027-52 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 77 USPATFULL on STN

Full Text

AN 2003:329987 USPATFULL
TI Immobilized bioactive hydrogel matrices as surface coatings
IN Lamberti, Francis V., Greenville, NC, UNITED STATES
Klann, Richard Chris, Washington, NC, UNITED STATES
Hill, Ronald Stewart, Greenville, NC, UNITED STATES
PA Encelle, Inc. (U.S. corporation)

PI US 2003232198 A1 20031218
AI US 2003-372757 A1 20030221 (10)
PRAI US 2002-358625P 20020221 (60)
DT Utility
FS APPLICATION
LN.CNT 1443
INCL INCLM: 428/423.100
INCLS: 428/480.000
NCL NCLM: 428/423.100
NCLS: 428/480.000
IC [7]
ICM B32B027-00
IPCI B32B0027-00 [ICM,7]
IPCR A61L0027-00 [I,C*]; A61L0027-34 [I,A]; A61L0031-08 [I,C*];
A61L0031-10 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 77 USPATFULL on STN

Full Text

AN 2003:293916 USPATFULL
TI BIOACTIVE, BIOABSORBABLE SURGICAL POLYETHYLENE GLYCOL AND POLYBUTYLENE TEREPHTALATE COPOLYMER COMPOSITES AND DEVICES
IN TORMALA, PERTTI, TAMPERE, FINLAND
KELLOMAKI, MINNA, TAMPERE, FINLAND
PI US 2003206928 A1 20031106
AI US 1999-287925 A1 19990407 (9)
DT Utility
FS APPLICATION
LN.CNT 876
INCL INCLM: 424/400.000
NCL NCLM: 424/400.000
IC [7]
ICM A61K031-765
ICS A61F002-00
IPCI A61K0031-765 [ICM,7]; A61K0031-74 [ICM,7,C*]; A61F0002-00 [ICS,7]
IPCR A61L0031-00 [I,C*]; A61L0031-00 [I,A]; A61L0031-12 [I,C*];
A61L0031-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 77 USPATFULL on STN

Full Text

AN 2003:250624 USPATFULL
TI Method and apparatus for preparing biomimetic scaffold
IN Campbell, Phil G., Pittsburgh, PA, UNITED STATES
Weiss, Lee E., Pittsburgh, PA, UNITED STATES
PI US 2003175410 A1 20030918
AI US 2003-391458 A1 20030318 (10)
PRAI US 2002-365451P 20020318 (60)
DT Utility
FS APPLICATION
LN.CNT 3292
INCL INCLM: 427/002.240
INCLS: 435/396.000; 623/023.720; 118/664.000
NCL NCLM: 427/002.240
NCLS: 118/664.000; 435/396.000; 623/023.720
IC [7]
ICM A61F002-02
IPCI A61F0002-02 [ICM,7]
IPCR C12N0005-00 [I,C*]; C12N0005-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 77 USPATFULL on STN

Full Text

AN 2003:245405 USPATFULL
TI Bone-implant prosthesis
IN Wilshaw, Peter Richard, Oxford, UNITED KINGDOM
Palsgard, Anna Eva Maria, Uppsala, SWEDEN
PI US 2003171820 A1 20030911
AI US 2003-332398 A1 20030307 (10)
WO 2001-GB3189 20010712
PRAI GB 2000-17148 20000712
DT Utility

FS APPLICATION
 LN.CNT 565
 INCL INCLM: 623/023.120
 INCLS: 623/023.550; 623/023.570; 623/901.000
 NCL NCLM: 623/023.120
 NCLS: 623/023.550; 623/023.570; 623/901.000
 IC [7]
 ICM A61F002-36
 ICS A61F002-28
 IPCI A61F0002-36 [ICM,7]; A61F0002-28 [ICS,7]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-30 [I,C*];
 A61F0002-30 [I,A]; A61F0002-32 [N,C*]; A61F0002-32 [N,A];
 A61F0002-36 [N,C*]; A61F0002-36 [N,A]; A61F0002-40 [N,A];
 A61K0006-02 [I,C*]; A61K0006-027 [I,A]; A61L0027-00 [I,C*];
 A61L0027-30 [I,A]; A61L0027-32 [I,A]; A61L0027-54 [I,A];
 C23C0028-00 [I,C*]; C23C0028-00 [I,A]

L16 ANSWER 40 OF 77 USPATFULL on STN

Full Text

AN 2003:86137 USPATFULL
 TI Osteointegration device and method,
 IN Webster, Thomas J., Lafayette, IN, UNITED STATES
 Tepper, Frederick, Sanford, FL, UNITED STATES
 PI US 2003059742 A1 20030327
 AI US 2002-253300 A1 20020924 (10)
 PRAI US 2001-324398P 20010924 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 693
 INCL INCLM: 433/201.100
 INCLS: 623/023.510
 NCL NCLM: 433/201.100
 NCLS: 623/023.510
 IC [7]
 ICM A61C008-00
 ICS A61F002-28
 IPCI A61C0008-00 [ICM,7]; A61F0002-28 [ICS,7]
 IPCR A61C0008-00 [I,C*]; A61C0008-00 [I,A]; A61F0002-00 [N,C*];
 A61F0002-00 [N,A]; A61F0002-30 [N,C*]; A61F0002-30 [N,A];
 A61K0035-12 [N,C*]; A61K0035-12 [N,A]; A61L0027-00 [I,C*];
 A61L0027-30 [I,A]; A61L0027-44 [I,A]; A61L0027-56 [I,A];
 C12N0005-06 [I,C*]; C12N0005-06 [I,A]

L16 ANSWER 41 OF 77 USPATFULL on STN

Full Text

AN 2003:40431 USPATFULL
 TI Compositions and methods for treating nails and adjacent tissues
 IN LaTorre, Guy, Gainesville, FL, United States
 Greenspan, David C., Gainesville, FL, United States
 Greenspan, Alice D., Gainesville, FL, United States
 PA USBiomaterials Corporation, Alachua, FL, United States (U.S.
 corporation)
 PI US 6517863 B1 20030211
 AI US 2000-488202 20000119 (9)
 PRAI US 1999-116595P 19990120 (60)
 DT Utility
 FS GRANTED
 LN.CNT 504
 INCL INCLM: 424/447.000
 INCLS: 424/405.000; 424/443.000; 424/445.000; 424/446.000; 424/061.000;
 514/722.400
 NCL NCLM: 424/447.000
 NCLS: 424/061.000; 424/405.000; 424/443.000; 424/445.000; 424/446.000;
 514/722.400
 IC [7]
 ICM A61L015-16
 ICS A61F013-00
 IPCI A61L0015-16 [ICM,7]; A61F0013-00 [ICS,7]
 IPCR A61K0008-04 [I,C*]; A61K0008-04 [I,A]; A61K0008-19 [I,C*];
 A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-41 [I,A];
 A61Q0003-02 [I,C*]; A61Q0003-02 [I,A]
 EXF 424/61; 424/405; 424/443; 424/445; 424/446; 424/447; 514/722.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 42 OF 77 USPATFULL on STN

Full Text

AN 2002:303741 USPATFULL
TI Silver-containing, sol/gel derived bioglass compositions
IN Bellantone, Maria, London, UNITED KINGDOM
Coleman, Nichola J., Kent, UNITED KINGDOM
Hench, Larry L., London, UNITED KINGDOM
PA Imperial College Innovations, London, UNITED KINGDOM (non-U.S.
corporation)
PI US 6482444 B1 20021119
AI US 2000-593868 20000614 (9)
PRAI US 1999-139014P 19990614 (60)
DT Utility
FS GRANTED
LN.CNT 1081
INCL INCLM: 424/618.000
NCL NCLM: 424/618.000
IC [7]
ICM A01N059-16
ICS A61K033-38
IPCI A01N0059-16 [ICM, 7]; A61K0033-38 [ICS, 7]
IPCR A61L0017-00 [I,C*]; A61L0017-00 [I,A]; A61L0027-00 [I,C*];
A61L0027-10 [I,A]; A61L0027-30 [I,A]; A61L0027-54 [I,A];
C03C0003-076 [I,C*]; C03C0003-078 [I,A]; C03C0003-097 [I,A];
C03C0004-00 [I,C*]; C03C0004-00 [I,A]; C03C0008-00 [I,C*];
C03C0008-08 [I,A]; C03C0013-00 [I,C*]; C03C0013-00 [I,A];
C03C0014-00 [I,C*]; C03C0014-00 [I,A]
EXF 424/400; 424/618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 77 USPATFULL on STN

Full Text

AN 2002:221889 USPATFULL
TI Dental/medical compositions comprising degradable polymers and methods
of manufacture thereof
IN Jia, Weitao, Wallingford, CT, UNITED STATES
Jin, Shuhua, Wallingford, CT, UNITED STATES
PI US 2002120033 A1 20020829
US 6787584 B2 20040907
AI US 2001-5298 A1 20011205 (10)
RLI Continuation-in-part of Ser. No. US 2000-638206, filed on 11 Aug 2000,
PENDING
PRAI US 2000-251408P 20001205 (60)
DT Utility
FS APPLICATION
LN.CNT 865
INCL INCLM: 523/115.000
NCL NCLM: 523/115.000
NCLS: 106/035.000; 433/228.100; 523/116.000; 523/117.000; 524/127.000;
528/354.000
IC [7]
ICM A61F002-00
ICS C08K003-00
IPCI A61F0002-00 [ICM, 7]; C08K0003-00 [ICS, 7]
IPCI-2 A61K0006-08 [ICM, 7]; A61K0006-087 [ICS, 7]; A61K0006-02
[ICS, 7,C*]; A61C0005-04 [ICS, 7]
IPCR A61K0006-00 [I,C*]; A61K0006-00 [I,A]; A61K0006-02 [I,C*];
A61K0006-083 [I,A]; A61L0024-00 [I,C*]; A61L0024-04 [I,A];
A61L0027-00 [I,C*]; A61L0027-44 [I,A]; A61L0027-46 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 77 USPATFULL on STN

Full Text

AN 2002:164425 USPATFULL
TI New cosmetic, personal care, cleaning agent, and nutritional supplement
compositions and methods of making and using same
IN Lee, Sean, Karlsruhe, GERMANY, FEDERAL REPUBLIC OF
Kessler, Susanna, Ergolding, GERMANY, FEDERAL REPUBLIC OF
Forberich, Oliver, Oberursel, GERMANY, FEDERAL REPUBLIC OF
Buchwar, Claire, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF

PI Greenspan, David C., Grainsville, FL, UNITED STATES
 US 2002086039 A1 20020704
 AI US 2001-818466 A1 20010327 (9)
 PRAI US 2000-192261P 20000327 (60)
 US 2000-197162P 20000414 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4825
 INCL INCLM: 424/401.000
 INCLS: 424/063.000; 424/064.000
 NCL NCLM: 424/401.000
 NCLS: 424/063.000; 424/064.000
 IC [7]
 ICM A61K007-021
 ICS A61K007-025; A61K007-00
 IPCI A61K007-021 [ICM, 7]; A61K007-025 [ICS, 7]; A61K007-00 [ICS, 7]
 IPCR A61K008-19 [I,C*]; A61K008-22 [I,A]; A61K008-25 [I,A];
 A61Q0001-02 [I,C*]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A];
 A61Q0003-00 [I,C*]; A61Q0003-00 [I,A]; A61Q0005-02 [I,C*];
 A61Q0005-02 [I,A]; A61Q0009-02 [I,C*]; A61Q0009-02 [I,A];
 A61Q0011-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0015-00 [I,C*];
 A61Q0015-00 [I,A]; A61Q0017-04 [I,C*]; A61Q0017-04 [I,A];
 A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]; A61Q0019-10 [I,C*];
 A61Q0019-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 77 USPATFULL on STN

Full Text

AN 2002:143771 USPATFULL
 TI Bioactive, bioabsorbable surgical composite material
 IN Tormala, Pertti, Tampere, FINLAND
 Valimaa, Tero, Tampere, FINLAND
 Niiranen, Henna, Tampere, FINLAND
 Pohjonen, Timo, Tampere, FINLAND
 Rokkanen, Penti, Helsinki, FINLAND
 PA Bionx Implants Oy, Tampere, FINLAND (non-U.S. corporation)
 PI US 6406498 B1 20020618
 AI US 1998-148838 19980904 (9)
 DT Utility
 FS GRANTED
 LN.CNT 970
 INCL INCLM: 623/023.750
 INCLS: 623/011.110
 NCL NCLM: 623/023.750
 NCLS: 623/011.110
 IC [7]
 ICM A61F002-36
 IPCI A61F002-36 [ICM, 7]
 IPCR A61L0017-00 [I,C*]; A61L0017-00 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]; A61L0027-44 [I,A]; A61L0031-12 [I,C*];
 A61L0031-12 [I,A]
 EXF 606/53; 623/11; 623/11.11; 623/23.75; 623/23.58; 623/23.61; 424/423;
 424/424

L16 ANSWER 46 OF 77 USPATFULL on STN

Full Text

AN 2002:61564 USPATFULL
 TI Osteogenic implants derived from bone
 IN Boyce, Todd M., Aberdeen, NJ, UNITED STATES
 Kaes, David, Toms River, NJ, UNITED STATES
 Scarborough, Nelson L., Ocean, NJ, UNITED STATES
 PA OSTEOTECH, INC. (U.S. corporation)
 PI US 2002035401 A1 20020321
 US 6808585 B2 20041026
 AI US 2001-973597 A1 20011009 (9)
 RLI Division of Ser. No. US 2000-610026, filed on 3 Jul 2000, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 1250
 INCL INCLM: 623/023.510
 INCLS: 264/175.000; 264/211.000; 264/211.110; 264/236.000; 264/320.000;
 264/322.000; 623/023.610

NCL NCLM: 156/244.110; 623/023.510
NCLS: 156/245.000; 156/296.000; 264/109.000; 435/372.000; 623/023.610;
623/023.630; 264/175.000; 264/211.000; 264/211.110; 264/236.000;
264/320.000; 264/322.000
IC [7]
ICM A61F002-28
ICS B29C047-00; B29C043-02; B29C043-24; B29C043-52
IPCI A61F0002-28 [ICM,7]; B29C0047-00 [ICS,7]; B29C0043-02 [ICS,7];
B29C0043-24 [ICS,7]; B29C0043-52 [ICS,7]
IPCI-2 A61F0002-28 [ICM,7]
IPCR A61L0027-00 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A];
A61L0027-00 [I,C*]; A61L0027-36 [I,A]

L16 ANSWER 47 OF 77 USPATFULL on STN

Full Text

AN 2001:165452 USPATFULL
TI Compositions and methods for repair of osseous defects and accelerated
wound healing
IN Yang, Shih-Liang S., Laguna Hills, CA, United States
PA Unicare Biomedical, Inc., Laguna Hills, CA (U.S. corporation)
PI US 2001024662 A1 20010927
US 6482427 B2 20021119
AI US 2001-814481 A1 20010315 (9)
RLI Continuation-in-part of Ser. No. US 1999-298683, filed on 23 Apr 1999,
GRANTED, Pat. No. US 6228386
DT Utility
FS APPLICATION
LN.CNT 984
INCL INCLM: 424/489.000
INCLS: 424/618.000
NCL NCLM: 424/426.000; 424/489.000
NCLS: 523/114.000; 523/115.000; 424/618.000
IC [7]
ICM A61K009-14
ICS A61K033-38
IPCI A61K0009-14 [ICM,7]; A61K0033-38 [ICS,7]
IPCI-2 A61F0002-28 [ICM,7]
IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-28 [N,A];
A61F0002-28 [N,C*]; A61L0024-00 [I,C*]; A61L0024-02 [I,A];
A61L0027-00 [I,C*]; A61L0027-10 [I,A]; C03C0003-076 [I,C*];
C03C0003-097 [I,A]; C03C0004-00 [I,A]; C03C0004-00 [I,C*];
C03C0012-00 [I,A]; C03C0012-00 [I,C*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 77 USPATFULL on STN

Full Text

AN 2001:154550 USPATFULL
TI Compositions and methods for intervertebral disc reformation
IN Gan, Jean Chin Chin, Ardmore, PA, United States
Ducheyne, Paul, Rosemont, PA, United States
Vresilovic, Edward, Philadelphia, PA, United States
Shapiro, Irving, Philadelphia, PA, United States
PA The Trustees of the University of Pennsylvania (U.S. corporation)
PI US 2001020476 A1 20010913
US 6569442 B2 20030527
AI US 2001-833284 A1 20010412 (9)
RLI Division of Ser. No. US 1999-314511, filed on 19 May 1999, GRANTED, Pat.
No. US 6240926 Division of Ser. No. US 1996-694191, filed on 8 Aug 1996,
GRANTED, Pat. No. US 5964807
DT Utility
FS APPLICATION
LN.CNT 776
INCL INCLM: 128/898.000
INCLS: 427/002.270; 623/919.000; 424/423.000; 427/002.100; 427/002.240;
623/017.160
NCL NCLM: 424/426.000; 128/898.000
NCLS: 128/898.000; 424/093.700; 424/423.000; 435/176.000; 435/177.000;
435/180.000; 435/325.000; 435/381.000; 435/395.000; 435/397.000;
623/017.160; 427/002.100; 427/002.240; 427/002.270; 623/919.000
IC [7]
ICM A61F002-28
ICS A61B019-00; A61F002-44

IPCI A61F0002-28 [ICM, 7]; A61B0019-00 [ICS, 7]; A61F0002-44 [ICS, 7];
 IPCI-2 A61F0002-44 [ICM, 7]; A01N0063-02 [ICS, 7]; C12N0011-14 [ICS, 7];
 C12N0011-08 [ICS, 7]; C12N0011-00 [ICS, 7,C*]; C12N0005-08 [ICS, 7];
 IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-02 [N,A];
 A61F0002-02 [N,C*]; A61F0002-30 [N,A]; A61F0002-30 [N,C*];
 A61F0002-44 [I,A]; A61F0002-44 [I,C*]; A61L0027-00 [I,C*];
 A61L0027-02 [I,A]; A61L0027-18 [I,A]; A61L0027-30 [I,A];
 A61L0027-38 [I,A]; A61L0027-44 [I,A]; A61L0027-56 [I,A]

L16 ANSWER 49 OF 77 USPATFULL on STN

Full Text

AN 2001:139311 USPATFULL
 TI Relic process for producing resorbable ceramic scaffolds
 IN Janas, Victor F., Monroe Township, NJ, United States
 TenHuisen, Kevor Shane, Clinton, NJ, United States
 PI US 2001016353 A1 20010823
 US 6667049 B2 20031223
 AI US 2001-819214 A1 20010328 (9)
 RLI Division of Ser. No. US 1999-333231, filed on 14 Jun 1999, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 507
 INCL INCLM: 435/395.000
 INCLS: 264/610.000
 NCL NCLM: 424/423.000; 435/395.000
 NCLS: 424/093.700; 435/176.000; 435/283.100; 435/284.100; 435/395.000;
 435/399.000; 264/610.000
 IC [7]
 ICM C12N005-08
 ICS C12N005-06; B28B001-00
 IPCI C12N0005-08 [ICM, 7]; C12N0005-06 [ICS, 7]; B28B0001-00 [ICS, 7];
 IPCI-2 A61F0002-00 [ICM, 7]; C12N0011-14 [ICS, 7]; C12N0011-00 [ICS, 7,C*];
 C12N0005-06 [ICS, 7]; C12N0005-08 [ICS, 7]; C12N0003-00 [ICS, 7];
 IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-02 [N,A];
 A61F0002-02 [N,C*]; A61F0002-28 [I,A]; A61F0002-28 [I,C*];
 A61F0002-30 [I,A]; A61F0002-30 [I,C*]; A61F0002-44 [N,A];
 A61F0002-44 [N,C*]; A61F0002-46 [N,A]; A61F0002-46 [N,C*];
 A61L0027-00 [I,C*]; A61L0027-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 50 OF 77 USPATFULL on STN

Full Text

AN 2001:81254 USPATFULL
 TI Compositions and methods for intervertebral disc reformation
 IN Chin Gan, Jean Chin, Ardmore, PA, United States
 Ducheyne, Paul, Rosemont, PA, United States
 Vresilovic, Edward, Philadelphia, PA, United States
 Shapiro, Irving, Philadelphia, PA, United States
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United
 States (U.S. corporation)
 PI US 6240926 B1 20010605
 AI US 1999-314511 19990519 (9)
 RLI Division of Ser. No. US 1996-694191, filed on 8 Aug 1996, now patented,
 Pat. No. US 5964807
 DT Utility
 FS Granted
 LN.CNT 725
 INCL INCLM: 128/898.000
 INCLS: 623/017.160
 NCL NCLM: 128/898.000
 NCLS: 623/017.160
 IC [7]
 ICM A61B019-00
 IPCI A61B0019-00 [ICM, 7]
 IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-02 [N,A];
 A61F0002-02 [N,C*]; A61F0002-30 [N,A]; A61F0002-30 [N,C*];
 A61F0002-44 [I,A]; A61F0002-44 [I,C*]; A61L0027-00 [I,C*];
 A61L0027-02 [I,A]; A61L0027-18 [I,A]; A61L0027-30 [I,A];
 A61L0027-38 [I,A]; A61L0027-44 [I,A]; A61L0027-56 [I,A];
 EXF 623/11; 623/17.16; 623/17.11; 623/23.51; 623/23.61; 623/23.63;
 623/16.11; 128/898

L16 ANSWER 51 OF 77 USPATFULL on STN

Full Text

AN 2001:63291 USPATFULL
TI Conditioning of bioactive glass surfaces in protein containing solutions
IN Ducheyne, Paul, Rosemont, PA, United States
Radin, Shulamith, Voorhees, NJ, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 6224913 B1 20010501
AI US 1997-977093 19971124 (8)
RLI Continuation-in-part of Ser. No. US 1996-647171, filed on 9 May 1996
DT Utility
FS Granted
LN.CNT 868
INCL INCLM: 424/602.000
INCLS: 424/422.000; 424/423.000; 424/426.000; 424/484.000; 424/485.000;
424/486.000; 424/489.000; 424/499.000; 424/603.000; 424/724.000;
424/531.000; 424/549.000; 523/218.000; 523/219.000; 623/908.000;
623/911.000; 623/919.000; 623/923.000
NCL NCLM: 424/602.000
NCLS: 424/422.000; 424/423.000; 424/426.000; 424/484.000; 424/485.000;
424/486.000; 424/489.000; 424/499.000; 424/531.000; 424/549.000;
424/603.000; 424/724.000; 523/218.000; 523/219.000; 623/908.000;
623/911.000; 623/919.000; 623/923.000
IC [7]
ICM A61K033-42
IPCI A61K0033-42 [ICM, 7]
IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61K0009-50 [I,A];
A61K0009-50 [I,C*]; A61L0027-00 [I,C*]; A61L0027-12 [I,A];
A61L0027-54 [I,A]
EXF 428/403; 428/404; 427/213.31; 427/215; 264/4.3; 264/4.4; 264/4.6;
106/690; 523/218; 523/219; 424/422; 424/423; 424/426; 424/484-486;
424/489; 424/491; 424/499; 424/602; 424/603; 424/724; 424/549; 424/531;
623/908; 623/911; 623/919; 623/923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 52 OF 77 USPATFULL on STN

Full Text

AN 2001:4660 USPATFULL
TI Bioactive sol-gel compositions and methods
IN Zhong, Jipin, Gainesville, FL, United States
Greenspan, David C., Gainesville, FL, United States
PA US Biomaterials Corp., Alachua, FL, United States (U.S. corporation)
PI US 6171986 B1 20010109
AI US 1998-6337 19980113 (9)
RLI Division of Ser. No. US 1997-834155, filed on 14 Apr 1997, now patented,
Pat. No. US 5874101
DT Patent
FS Granted
LN.CNT 518
INCL INCLM: 501/012.000
INCLS: 501/039.000; 501/057.000; 501/058.000; 501/063.000; 106/035.000;
623/016.000
NCL NCLM: 501/012.000
NCLS: 106/035.000; 501/039.000; 501/057.000; 501/058.000; 501/063.000
IC [7]
ICM C03C003-16
ICS C03C003-247
IPCI C03C0003-16 [ICM, 7]; C03C0003-247 [ICS, 7]; C03C0003-12 [ICS, 7,C*]
IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-02 [N,A];
A61F0002-02 [N,C*]; A61F0002-28 [N,A]; A61F0002-28 [N,C*];
A61F0002-30 [N,A]; A61F0002-30 [N,C*]; A61L0027-00 [I,C*];
A61L0027-10 [I,A]; A61L0027-12 [I,A]; C03B0019-00 [I,C*];
C03B0019-10 [I,A]; C03B0019-12 [I,A]; C03B0019-12 [I,C*];
C03C0001-00 [I,A]; C03C0001-00 [I,C*]; C03C0004-00 [I,A];
C03C0004-00 [I,C*]
EXF 501/39; 501/12; 501/57; 501/58; 501/63; 106/35; 623/16

L16 ANSWER 53 OF 77 USPATFULL on STN

Full Text

AN 2000:174115 USPATFULL
TI Biocompatible compositions and methods of using same

IN Marra, Kacey G., Pittsburg, PA, United States
 Weiss, Lee E., Pittsburg, PA, United States
 Calvert, Jay Wynn, Pittsburg, PA, United States
 Kumta, Prashant N., Pittsburg, PA, United States
 PA Carnegie Mellon University, Pittsburgh, PA, United States (U.S. corporation)
 University of Pittsburgh, Pittsburgh, PA, United States (U.S. corporation)
 PI US 6165486 20001226
 AI US 1998-196288 19981119 (9)
 DT Utility
 FS Granted
 LN.CNT 1010
 INCL INCLM: 424/423.000
 INCLS: 424/422.000; 424/424.000; 424/425.000; 424/428.000
 NCL NCLM: 424/423.000
 NCLS: 424/422.000; 424/424.000; 424/425.000; 424/428.000
 IC [7]
 ICM A61F002-00
 ICS A61F013-00
 IPCI A61F0002-00 [ICM, 7]; A61F0013-00 [ICS, 7]
 IPCR A61L0027-00 [I, C*]; A61L0027-46 [I, A]
 EXF 424/423; 424/425; 606/230; 128/90
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 54 OF 77 USPATFULL on STN

Full Text

AN 2000:124949 USPATFULL
 TI Composite materials using bone **bioactive glass** and ceramic fibers
 IN Marcolongo, Michele S., Lansdowne, PA, United States
 Ducheyne, Paul, Rosemont, PA, United States
 Ko, Frank, Philadelphia, PA, United States
 LaCourse, William, Alfred, NY, United States
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
 PI US 6121172 20000919
 AI US 1995-461109 19950605 (8)
 RLI Division of Ser. No. US 1995-436585, filed on 8 May 1995, now patented, Pat. No. US 5645934 which is a continuation-in-part of Ser. No. US 1993-152962, filed on 15 Nov 1993, now patented, Pat. No. US 5468544
 DT Utility
 FS Granted
 LN.CNT 910
 INCL INCLM: 442/301.000
 INCLS: 442/005.000; 442/021.000; 442/043.000; 442/060.000; 428/411.100;
 623/011.000; 623/016.000; 501/035.000; 433/201.100; 424/076.800
 NCL NCLM: 442/301.000
 NCLS: 424/076.800; 428/411.100; 433/201.100; 442/005.000; 442/021.000;
 442/043.000; 442/060.000; 501/035.000; 623/022.110; 623/023.610
 IC [7]
 ICM B32B018-00
 ICS C04B033-24
 IPCI B32B0018-00 [ICM, 7]; C04B0033-24 [ICS, 7]; C04B0033-00 [ICS, 7, C*]
 IPCR A61F0002-00 [N, A]; A61F0002-00 [N, C*]; A61F0002-30 [I, A];
 A61F0002-30 [I, C*]; A61F0002-36 [I, A]; A61F0002-36 [I, C*];
 A61L0027-00 [I, C*]; A61L0027-02 [I, A]; A61L0027-10 [I, A];
 A61L0027-42 [I, A]; A61L0027-44 [I, A]; C03C0013-00 [I, A];
 C03C0013-00 [I, C*]; D03D0015-00 [I, A]; D03D0015-00 [I, C*]
 EXF 428/224; 428/247; 428/280; 428/411.1; 623/11; 623/16; 501/35; 433/201.1;
 424/76.8; 106/35; 523/114; 524/443; 442/5; 442/21; 442/43; 442/60;
 442/301
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 55 OF 77 USPATFULL on STN

Full Text

AN 2000:1556 USPATFULL
 TI Bioactive sol-gel compositions and methods
 IN Zhong, Jipin, Gainesville, FL, United States
 Greenspan, David C., Gainesville, FL, United States
 PA US Biomaterials Corp., Alachua, FL, United States (U.S. corporation)
 PI US 6010713 20000104
 AI US 1998-6630 19980113 (9)

RLI Division of Ser. No. US 1997-834155, filed on 14 Apr 1997, now patented,
 Pat. No. US 5874101
 DT Utility
 FS Granted
 LN.CNT 515
 INCL INCLM: 424/426.000
 INCLS: 523/114.000; 523/115.000; 523/116.000; 623/016.000
 NCL NCLM: 424/426.000
 NCLS: 523/114.000; 523/115.000; 523/116.000; 623/023.480
 IC [6]
 ICM A61F002-16
 ICS A61K006-08
 IPCI A61F0002-16 [ICM,6]; A61K0006-08 [ICS,6]; A61K0006-02 [ICS,6,C*]
 IPCR A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-00 [N,C*];
 A61F0002-00 [N,A]; A61F0002-02 [N,C*]; A61F0002-02 [N,A];
 A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61L0027-00 [I,C*];
 A61L0027-10 [I,A]; A61L0027-12 [I,A]; C03B0019-00 [I,C*];
 C03B0019-10 [I,A]; C03B0019-12 [I,C*]; C03B0019-12 [I,A];
 C03C0001-00 [I,C*]; C03C0001-00 [I,A]; C03C0004-00 [I,C*];
 C03C0004-00 [I,A]
 EXF 424/426; 523/114; 523/115; 523/116; 623/16

L16 ANSWER 56 OF 77 USPATFULL on STN

Full Text

AN 2000:569 USPATFULL
 TI Process for preparing glass and for conditioning the raw materials
 intended for this glass preparation
 IN Helsen, Jozef A., Zavelstraat 2B, B-3010 Leuven, Belgium
 Proost, Joris, Kruisberg 22, B-2400 Mol, Belgium
 Brauns, Etienne, Lemmensblok 2, B-2400 Mol, Belgium
 PI US 6009724 20000104
 WO 9629292 19960926
 AI US 1997-913570 19970917 (8)
 WO 1996-BE29 19960315
 19970917 PCT 371 date
 19970917 PCT 102(e) date
 PRAI BE 1995-242 19950317
 DT Utility
 FS Granted
 LN.CNT 641
 INCL INCLM: 065/017.300
 INCLS: 065/391.000; 065/021.100; 065/136.100; 065/144.000
 NCL NCLM: 065/017.300
 NCLS: 065/021.100; 065/136.100; 065/144.000; 065/391.000
 IC [6]
 ICM C03B009-00
 ICS C03B019-10; C03B023-00; C03B037-00
 IPCI C03B0009-00 [ICM,6]; C03B0019-10 [ICS,6]; C03B0019-00 [ICS,6,C*];
 C03B0023-00 [ICS,6]; C03B0037-00 [ICS,6]
 IPCR C03B0005-00 [I,C*]; C03B0005-02 [I,A]; C03B0019-00 [I,C*];
 C03B0019-01 [I,A]; C03B0019-06 [I,C*]; C03B0019-06 [I,A];
 C03B0019-10 [I,A]; C03B0032-00 [I,C*]; C03B0032-00 [I,A];
 C03C0012-00 [I,C*]; C03C0012-00 [I,A]
 EXF 065/391; 065/414; 065/421; 065/436; 065/17.3; 065/21.1; 065/21.3;
 065/60.5; 065/60.8; 065/134.1; 065/135.9; 065/136.1; 065/142; 065/144;
 501/27; 501/53; 501/55; 501/56; 501/58; 501/61; 501/63
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 57 OF 77 USPATFULL on STN

Full Text

AN 1999:124145 USPATFULL
 TI Compositions and methods for intervertebral disc reformation
 IN Gan, Jean Chin Chin, Ardmore, PA, United States
 Ducheyne, Paul, Rosemont, PA, United States
 Vresilovic, Edward, Philadelphia, PA, United States
 Shapiro, Irving, Philadelphia, PA, United States
 PA Trustees of the University of Pennsylvania, Philadelphia, PA, United
 States (U.S. corporation)
 PI US 5964807 19991012
 AI US 1996-694191 19960808 (8)
 DT Utility
 FS Granted

LN.CNT 733
 INCL INCLM: 623/017.000
 INCLS: 623/011.000; 623/016.000; 427/002.100; 427/002.240
 NCL NCLM: 424/423.000
 NCLS: 427/002.100; 427/002.240; 623/017.160
 IC [6]
 ICM A61F002-44
 IPCI A61F0002-44 [ICM,6]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-02 [N,C*];
 A61F0002-02 [N,A]; A61F0002-30 [N,C*]; A61F0002-30 [N,A];
 A61F0002-44 [I,C*]; A61F0002-44 [I,A]; A61L0027-00 [I,C*];
 A61L0027-02 [I,A]; A61L0027-18 [I,A]; A61L0027-30 [I,A];
 A61L0027-38 [I,A]; A61L0027-44 [I,A]; A61L0027-56 [I,A]
 EXF 623/11; 623/16; 623/17; 623/18; 427/2.1; 427/2.24

L16 ANSWER 58 OF 77 USPATFULL on STN

Full Text

AN 1999:69745 USPATFULL
 TI Bioactive load bearing bone bonding compositions
 IN Erbe, Erik M., Berwyn, PA, United States
 PA Orthovita, Inc., Malvern, PA, United States (U.S. corporation)
 PI US 5914356 19990622
 WO 9720521 19970612
 AI US 1998-77709 19980605 (9)
 WO 1996-US19368 19961206
 19980605 PCT 371 date
 19980605 PCT 102(e) date
 DT Utility
 FS Granted
 LN.CNT 1801
 INCL INCLM: 523/114.000
 INCLS: 523/113.000; 523/115.000; 524/414.000; 524/456.000; 106/035.000;
 106/634.000; 106/691.000; 501/072.000; 501/073.000; 065/033.100;
 623/016.000D
 NCL NCLM: 523/114.000
 NCLS: 065/033.100; 106/035.000; 106/634.000; 106/691.000; 501/072.000;
 501/073.000; 523/113.000; 523/115.000; 524/414.000; 524/456.000
 IC [6]
 ICM A61K006-06
 ICS C08K003-40
 IPCI A61K0006-06 [ICM,6]; A61K0006-02 [ICM,6,C*]; C08K0003-40 [ICS,6];
 C08K0003-00 [ICS,6,C*]
 IPCR A61K0006-02 [I,C*]; A61K0006-083 [I,A]; A61L0024-00 [I,C*];
 A61L0024-00 [I,A]; A61L0024-02 [I,A]; C03C0010-00 [I,C*];
 C03C0010-00 [I,A]
 EXF 523/113; 523/114; 523/115; 524/414; 524/456; 106/35; 106/634; 106/691;
 501/72; 501/73; 065/33.1; 623/16D
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 59 OF 77 USPATFULL on STN

Full Text

AN 1999:24327 USPATFULL
 TI Bioactive-gel compositions and methods
 IN Zhong, Jipin, Gainesville, FL, United States
 Greenspan, David C., Gainesville, FL, United States
 PA US Biomaterials Corp., Alachua, FL, United States (U.S. corporation)
 PI US 5874101 19990223
 AI US 1997-834155 19970414 (8)
 DT Utility
 FS Granted
 LN.CNT 579
 INCL INCLM: 424/426.000
 INCLS: 523/114.000; 523/115.000; 523/116.000
 NCL NCLM: 424/426.000
 NCLS: 523/114.000; 523/115.000; 523/116.000
 IC [6]
 ICM A61F002-28
 IPCI A61F0002-28 [ICM,6]
 IPCR A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-00 [N,C*];
 A61F0002-00 [N,A]; A61F0002-02 [N,C*]; A61F0002-02 [N,A];
 A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61L0027-00 [I,C*];
 A61L0027-10 [I,A]; A61L0027-12 [I,A]; C03B0019-00 [I,C*];

C03B0019-10 [I,A]; C03B0019-12 [I,C*]; C03B0019-12 [I,A];
C03C0001-00 [I,C*]; C03C0001-00 [I,A]; C03C0004-00 [I,C*];
C03C0004-00 [I,A]

EXF 523/114; 523/115; 523/116; 424/426

L16 ANSWER 60 OF 77 USPATFULL on STN

Full Text

AN 1998:119071 USPATFULL
TI Colloidal silica films for cell culture
IN Wolcott, Christine C., Horseheads, NY, United States
PA Corning Incorporated, United States (U.S. corporation)
PI US 5814550 19980929
AI US 1996-721152 19960926 (8)
PRAI US 1995-5039P 19951006 (60)
DT Utility
FS Granted
LN.CNT 1125
INCL INCLM: 435/402.000
INCLS: 435/289.100; 435/305.100
NCL NCLM: 435/402.000
NCLS: 435/289.100; 435/305.100
IC [6]
ICM C12M003-04
IPCI C12M003-04 [ICM,6]
IPCR C12N0005-00 [I,C*]; C12N0005-00 [I,A]; C12N0005-06 [I,C*];
C12N0005-06 [I,A]
EXF 117/76; 117/152; 117/169; 428/403; 435/305.1; 435/325; 435/395; 435/402;
435/284; 435/283.1; 435/289.1

L16 ANSWER 61 OF 77 USPATFULL on STN

Full Text

AN 1998:48308 USPATFULL
TI Hard tissue bone cements and substitutes
IN Cooper, Kevin, Warren, NJ, United States
Chen, Chao C., Edison, NJ, United States
Scopelianos, Angelo, Whitehouse Station, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 5747390 19980505
AI US 1996-603570 19960220 (8)
RLI Continuation of Ser. No. US 1995-416383, filed on 6 Apr 1995, now
abandoned which is a division of Ser. No. US 1994-346652, filed on 30
Nov 1994, now abandoned
DT Utility
FS Granted
LN.CNT 818
INCL INCLM: 442/059.000
INCLS: 442/164.000; 442/417.000; 528/354.000; 528/355.000; 528/358.000;
623/016.000; 428/375.000
NCL NCLM: 442/059.000
NCLS: 428/375.000; 442/164.000; 442/417.000; 528/354.000; 528/355.000;
528/358.000
IC [6]
ICM A61F002-28
ICS B32B027-36
IPCI A61F0002-28 [ICM,6]; B32B0027-36 [ICS,6]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61L0024-00 [I,C*];
A61L0024-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-32 [I,A];
C08J0003-20 [I,C*]; C08J0003-20 [I,A]
EXF 442/59; 442/164; 442/417; 528/354; 528/355; 528/358; 623/16; 428/375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 62 OF 77 USPATFULL on STN

Full Text

AN 1998:19527 USPATFULL
TI Composite materials using bone bioactive glass and ceramic fibers
IN Marcolongo, Michele S., Lansdowne, PA, United States
Ducheyne, Paul, Rosemont, PA, United States
Ko, Frank, Philadelphia, PA, United States
LaCourse, William, Alfred, NY, United States
PA Trustees of the University of Pennsylvania, Philadelphia, PA, United
States (U.S. corporation)
PI US 5721049 19980224

AI US 1995-463009 19950605 (8)
 RLI Division of Ser. No. US 1995-436585, filed on 8 May 1995 which is a continuation-in-part of Ser. No. US 1993-152962, filed on 15 Nov 1993, now patented, Pat. No. US 5468544, issued on 21 Nov 1995
 DT Utility
 FS Granted
 LN.CNT 907
 INCL INCLM: 428/370.000
 INCLS: 428/300.400; 428/357.000; 428/361.000; 428/373.000; 428/374.000;
 428/411.100; 623/011.000; 623/016.000; 501/035.000; 501/055.000;
 501/063.000; 501/068.000
 NCL NCLM: 428/370.000
 NCLS: 424/423.000; 428/300.400; 428/357.000; 428/361.000; 428/373.000;
 428/374.000; 428/411.100; 501/035.000; 501/055.000; 501/063.000;
 501/068.000
 IC [6]
 ICM C04B033-24
 ICS C03C003-076; B32B017-04
 IPCI C04B0033-24 [ICM,6]; C04B0033-00 [ICM,6,C*]; C03C0003-076
 [ICS,6]; B32B0017-04 [ICS,6]
 IPCR A61F0002-00 [N,C*]; A61F0002-30 [I,C*];
 A61F0002-30 [I,A]; A61F0002-36 [I,C*]; A61F0002-36 [I,A];
 A61L0027-00 [I,C*]; A61L0027-02 [I,A]; A61L0027-10 [I,A];
 A61L0027-42 [I,A]; A61L0027-44 [I,A]; C03C0013-00 [I,C*];
 C03C0013-00 [I,A]; D03D0015-00 [I,C*]; D03D0015-00 [I,A]
 EXF 623/11; 623/16; 501/35; 501/55; 501/63; 501/68; 433/201.1; 424/76.8;
 106/35; 523/114; 524/443; 428/224; 428/247; 428/280; 428/411.1; 428/357;
 428/361; 428/370; 428/373; 428/324
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 63 OF 77 USPATFULL on STN

Full Text

AN 97:99322 USPATFULL
 TI Bioactive load bearing bone graft compositions
 IN Erbe, Erik M., Berwyn, PA, United States
 PA Orthovita, Inc., Malvern, PA, United States (U.S. corporation)
 PI US 5681872 19971028
 AI US 1995-568812 19951207 (8)
 DT Utility
 FS Granted
 LN.CNT 1559
 INCL INCLM: 523/114.000
 INCLS: 523/113.000; 523/115.000; 524/456.000; 524/414.000; 260/998.110;
 106/035.000; 106/634.000; 106/691.000; 501/070.000
 NCL NCLM: 523/114.000
 NCLS: 106/035.000; 106/634.000; 106/691.000; 260/998.110; 501/070.000;
 523/113.000; 523/115.000; 524/414.000; 524/456.000
 IC [6]
 ICM A61K006-06
 ICS C08K003-40
 IPCI A61K0006-06 [ICM,6]; A61K0006-02 [ICM,6,C*]; C08K0003-40 [ICS,6];
 C08K0003-00 [ICS,6,C*]
 IPCR A61C0008-00 [I,C*]; A61C0008-00 [I,A]; A61B0017-68 [I,C*];
 A61B0017-86 [I,A]; A61F0002-28 [I,C*]; A61F0002-28 [I,A];
 A61F0002-30 [N,C*]; A61F0002-30 [N,A]; A61F0002-32 [I,C*];
 A61F0002-32 [I,A]; A61F0002-44 [I,C*]; A61F0002-44 [I,A];
 A61F0002-46 [I,C*]; A61F0002-46 [I,A]; A61K0006-02 [I,C*];
 A61K0006-06 [I,A]; A61K0006-083 [I,A]; A61L0027-00 [I,C*];
 A61L0027-02 [I,A]; A61L0027-44 [I,A]; A61L0027-46 [I,A];
 A61L0031-00 [I,C*]; A61L0031-00 [I,A]; C03C0010-00 [I,C*];
 C03C0010-00 [I,A]; C08K0003-00 [I,C*]; C08K0003-34 [I,A];
 C08L0033-00 [I,C*]; C08L0033-10 [I,A]; C08L0101-00 [I,C*];
 C08L0101-00 [I,A]
 EXF 523/114; 523/115; 523/113; 524/456; 524/414; 260/998.11; 106/35;
 106/634; 106/691; 501/70
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 64 OF 77 USPATFULL on STN

Full Text

AN 97:96913 USPATFULL
 TI Hard tissue bone cements and substitutes
 IN Cooper, Kevin, Warren, NJ, United States

Chen, Chao C., Edison, NJ, United States
 Scopelianos, Angelo, Whitehouse Station, NJ, United States
 PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
 PI US 5679723 19971021
 AI US 1996-710691 19960919 (8)
 RLI Continuation of Ser. No. US 1995-416389, filed on 6 Apr 1995, now
 abandoned which is a division of Ser. No. US 1994-346652, filed on 30
 Nov 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 885
 INCL INCLM: 523/115.000
 INCLS: 424/426.000; 428/245.000; 528/358.000; 623/016.000
 NCL NCLM: 523/115.000
 NCLS: 424/426.000; 528/358.000
 IC [6]
 ICM A61F002-02
 ICS A61F002-28; C08G063-82
 IPCI A61F0002-02 [ICM,6]; A61F0002-28 [ICS,6]; C08G0063-82 [ICS,6];
 C08G0063-00 [ICS,6,C*]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61L0024-00 [I,C*];
 A61L0024-00 [I,A]; A61L0027-00 [I,C*]; A61L0027-44 [I,A];
 A61L0027-46 [I,A]; A61L0027-58 [I,A]; C08J0003-20 [I,C*];
 C08J0003-20 [I,A]
 EXF 424/426; 428/240; 428/245; 428/254; 428/262; 428/281; 428/289; 428/323;
 428/330; 428/480; 528/354; 528/355; 528/358; 623/16; 523/115
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 65 OF 77 USPATFULL on STN

Full Text

AN 97:58999 USPATFULL
 TI Composite materials using bone **bioactive glass** and ceramic fibers
 IN Marcolongo, Michele S., Lansdowne, PA, United States
 Ducheyne, Paul, Rosemont, PA, United States
 PA Trustees Of The University Of Pennsylvania, Philadelphia, PA, United
 States (U.S. corporation)
 PI US 5645934 19970708
 AI US 1995-436585 19950508 (8)
 RLI Continuation-in-part of Ser. No. US 1993-152962, filed on 15 Nov 1993,
 now patented, Pat. No. US 5468544
 DT Utility
 FS Granted
 LN.CNT 897
 INCL INCLM: 428/357.000
 INCLS: 428/392.000; 428/397.000; 623/011.000; 623/016.000; 501/035.000;
 433/201.100; 424/076.800; 106/035.000; 523/114.000
 NCL NCLM: 428/357.000
 NCLS: 106/035.000; 424/076.800; 428/392.000; 428/397.000; 433/201.100;
 501/035.000; 523/114.000; 623/023.510
 IC [6]
 ICM C04B033-24
 ICS C04B035-44
 IPCI C04B0033-24 [ICM,6]; C04B0033-00 [ICM,6,C*]; C04B0035-44 [ICS,6]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-30 [I,C*];
 A61F0002-30 [I,A]; A61F0002-36 [I,C*]; A61F0002-36 [I,A];
 A61L0027-00 [I,C*]; A61L0027-02 [I,A]; A61L0027-10 [I,A];
 A61L0027-42 [I,A]; A61L0027-44 [I,A]; C03C0013-00 [I,C*];
 C03C0013-00 [I,A]; D03D0015-00 [I,C*]; D03D0015-00 [I,A]
 EXF 428/392; 428/397; 428/357; 623/11; 623/16; 501/35; 433/201.1; 424/76.8;
 106/35; 523/114; 524/443
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 66 OF 77 USPATFULL on STN

Full Text

AN 96:77825 USPATFULL
 TI Utilization of biocompatible adhesive/sealant materials for securing
 surgical devices
 IN Regula, Donald W., Belle Mead, NJ, United States
 Cooper, Kevin, Warren, NJ, United States
 Bregen, Michael F., Milford, NJ, United States
 Huxel, Shawn T., Lakehurst, NJ, United States
 Rosenman, Daniel C., San Mateo, CA, United States

PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
 PI US 5550172 19960827
 AI US 1995-385015 19950207 (8)
 DT Utility
 FS Granted
 LN.CNT 595
 INCL INCLM: 523/118.000
 INCLS: 606/076.000; 606/077.000; 528/354.000; 423/305.000; 423/308.000;
 423/309.000; 423/311.000
 NCL NCLM: 523/118.000
 NCLS: 423/305.000; 423/308.000; 423/309.000; 423/311.000; 528/354.000;
 606/076.000; 606/077.000
 IC [6]
 ICM C08K005-10
 ICS A61B017-56; A61B017-58; C01B015-16
 IPCI C08K0005-10 [ICM,6]; C08K0005-00 [ICM,6,C*]; A61B0017-56 [ICS,6];
 A61B0017-58 [ICS,6]; C01B0015-16 [ICS,6]; C01B0015-00 [ICS,6,C*]
 IPCR A61L0024-00 [I,A]; A61L0024-00 [I,C*]; A61L0024-02 [I,A];
 A61L0024-04 [I,A]; A61L0024-06 [I,A]; A61L0027-00 [I,C*];
 A61L0027-00 [I,A]
 EXF 523/118; 606/76; 606/77; 528/354; 528/363; 524/436; 423/305; 423/308;
 423/309; 423/311
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 67 OF 77 USPATFULL on STN

Full Text

AN 94:106395 USPATFULL
 TI Rapid, customized bone prosthesis
 IN Fink, David J., Marble Cliff, OH, United States
 DiNovo, Salvatore T., Columbus, OH, United States
 Ward, Thomas J., Columbus, OH, United States
 PA Guild Associates, Inc., Hilliard, OH, United States (U.S. corporation)
 PI US 5370692 19941206
 AI US 1992-929449 19920814 (7)
 DT Utility
 FS Granted
 LN.CNT 499
 INCL INCLM: 623/016.000
 INCLS: 623/066.000
 NCL NCLM: 128/898.000
 NCLS: 264/401.000; 264/494.000; 600/587.000; 623/901.000; 623/914.000;
 700/120.000
 IC [5]
 ICM A61F002-28
 IPCI A61F0002-28 [ICM,5]
 IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-30 [I,C*];
 A61F0002-30 [I,A]; B29C0041-34 [I,C*]; B29C0041-36 [I,A];
 B29C0067-00 [I,C*]; B29C0067-00 [I,A]; G05B0019-4097 [I,C*];
 G05B0019-4099 [I,A]
 EXF 623/16; 623/18; 623/66

L16 ANSWER 68 OF 77 USPATFULL on STN

Full Text

AN 92:102645 USPATFULL
 TI Calcium phosphate ceramics for bone tissue calcification enhancement
 IN Ducheyne, Paul, Bryn Mawr, PA, United States
 Cuckler, John, Haverford, PA, United States
 Radin, Shulamit, Cherry Hill, NJ, United States
 PA Trustees of the University of Pennsylvania, Philadelphia, PA, United
 States (U.S. corporation)
 PI US 5171326 19921215
 AI US 1992-840604 19920220 (7)
 RLI Continuation of Ser. No. US 1990-601943, filed on 22 Oct 1990 which is a
 division of Ser. No. US 1989-307326, filed on 6 Feb 1989, now patented,
 Pat. No. US 4990163, issued on 5 Feb 1991
 DT Utility
 FS Granted
 LN.CNT 896
 INCL INCLM: 623/066.000
 INCLS: 423/305.000
 NCL NCLM: 623/066.100
 NCLS: 423/305.000; 623/923.000

IC [5]
ICM A61F002-54
IPCI A61F0002-54 [ICM,5]; A61F0002-50 [ICM,5,C*]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-30 [I,C*];
A61F0002-30 [I,A]; A61L0027-00 [I,C*]; A61L0027-32 [I,A]
EXF 623/11; 623/16; 623/66; 423/305; 435/240.1; 435/241; 427/2

L16 ANSWER 69 OF 77 USPATFULL on STN

Full Text

AN 91:10472 USPATFULL
TI Method of depositing calcium phosphate cermamics for bone tissue
calcification enhancement
IN Ducheyne, Paul, Bryn Mawr, PA, United States
Cuckler, John, Haverford, PA, United States
Radin, Shulamit, Cherry Hill, NJ, United States
PA Trustees of the University of Pennsylvania, Philadelphia, PA, United
States (U.S. corporation)
PI US 4990163 19910205
AI US 1989-307326 19890206 (7)
DT Utility
FS Granted
LN.CNT 966
INCL INCLM: 623/066.000
INCLS: 623/016.000; 427/002.000
NCL NCLM: 427/002.240
NCLS: 204/491.000; 427/002.270; 623/023.560; 623/923.000
IC [5]
ICM A61F002-28
IPCI A61F0002-28 [ICM,5]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61F0002-30 [I,C*];
A61F0002-30 [I,A]; A61L0027-00 [I,C*]; A61L0027-32 [I,A]
EXF 623/16; 623/66; 623/901; 427/2; 501/95

L16 ANSWER 70 OF 77 USPATFULL on STN

Full Text

AN 88:64020 USPATFULL
TI Fluoride-containing Bioglass.TM. compositions
IN Hench, Larry L., Gainesville, FL, United States
Spilman, Derek B., Gainesville, FL, United States
Hench, June W., Gainesville, FL, United States
PA University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 4775646 19881004
AI US 1986-906619 19860910 (6)
RLI Continuation of Ser. No. US 1984-604704, filed on 27 Apr 1984, now
abandoned
DT Utility
FS Granted
LN.CNT 558
INCL INCLM: 501/002.000
INCLS: 501/001.000; 501/057.000; 623/016.000; 128/092.000R; 428/432.000
NCL NCLM: 501/002.000
NCLS: 428/432.000; 501/001.000; 501/057.000; 606/076.000; 623/023.610
IC [4]
ICM C03C010-00
IPCI C03C0010-00 [ICM,4]
IPCR A61F0002-00 [N,C*]; A61F0002-00 [N,A]; A61K0006-02 [I,C*];
A61K0006-06 [I,A]; A61L0027-00 [I,C*]; A61L0027-12 [I,A];
A61L0027-32 [I,A]; C03C0003-076 [I,C*]; C03C0003-097 [I,A];
C03C0004-00 [I,C*]; C03C0004-00 [I,A]
EXF 501/2; 501/57; 501/72; 003/1.9; 128/92C; 428/432-434; 623/16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 71 OF 77 USPATFULL on STN

Full Text

AN 84:14895 USPATFULL
TI Implant of ceramic material
IN van der Zel, Joseph M., Zwaag, Netherlands
de Groot, Klaas, Heemstede, Netherlands
PA Delphi Dental Industries B.V., Le Hoorn, Netherlands (non-U.S.
corporation)
PI US 4437191 19840320
AI US 1982-364975 19820402 (6)

PRAI NL 1981-1674 19810403
 DT Utility
 FS Granted
 LN.CNT 185
 INCL INCLM: 003/001.000
 INCLS: 003/001.900; 128/092.000C; 128/092.000G
 NCL NCLM: 623/023.560
 NCLS: 606/076.000
 IC [3]
 ICM A61F001-00
 IPCI A61F0001-00 [ICM,3]
 IPCR A61C0008-00 [I,C*]; A61C0008-00 [I,A]; A61F0002-00 [N,C*];
 A61F0002-00 [N,A]; A61F0002-02 [I,C*]; A61F0002-02 [I,A];
 A61F0002-28 [I,C*]; A61F0002-28 [I,A]; A61F0002-30 [I,C*];
 A61F0002-30 [I,A]; A61K0006-02 [I,C*]; A61K0006-02 [I,A];
 A61L0027-00 [I,C*]; A61L0027-00 [I,A]; B28B0023-02 [I,C*];
 B28B0023-04 [I,A]
 EXF 003/1; 003/1.9; 128/92B; 128/92BC; 128/92C; 128/92D; 128/92G

L16 ANSWER 72 OF 77 USPAT2 on STN

Full Text

AN 2002:337866 USPAT2
 TI Glassy-crystalline material with low solubility and process of preparing
 the same
 IN Berger, Georg, Zepernick, GERMANY, FEDERAL REPUBLIC OF
 Ploska, Ute, Berlin, GERMANY, FEDERAL REPUBLIC OF
 PA Bam Bundesanstalt fuer Materialforschung und Prufung, GERMANY, FEDERAL
 REPUBLIC OF (non-U.S. corporation)
 PI US 6767854 B2 20040727
 AI US 2002-170779 20020613 (10)
 PRAI DE 2001-10129844 20010615
 DE 2002-10223102 20020517
 DT Utility
 FS GRANTED
 LN.CNT 497
 INCL INCLM: 501/010.000
 INCLS: 501/001.000; 501/032.000; 501/102.000; 501/044.000; 501/046.000;
 065/033.300
 NCL NCLM: 501/010.000; 501/032.000
 NCLS: 065/033.300; 501/001.000; 501/032.000; 501/044.000; 501/046.000;
 501/102.000; 501/003.000
 IC [7]
 ICM C03C010-02
 ICS C03C001-00; C03C003-247; C03C010-16
 IPCI C03C0014-00 [ICM,7]; C03C0010-02 [ICS,7]; C03C0010-16 [ICS,7];
 C03C0010-00 [ICS,7,C*]
 IPCI-2 C03C0010-02 [ICM,7]; C03C0001-00 [ICS,7]; C03C0003-247 [ICS,7];
 C03C0003-12 [ICS,7,C*]; C03C0010-16 [ICS,7]; C03C0010-00
 [ICS,7,C*]
 IPCR A61L0027-00 [I,C*]; A61L0027-12 [I,A]; A61L0027-32 [I,A];
 C03C0010-00 [I,C*]; C03C0010-02 [I,A]; C03C0010-16 [I,A]
 EXF 501/1; 501/10; 501/32; 501/44-46; 501/102; 065/33.3
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 73 OF 77 USPAT2 on STN

Full Text

AN 2002:221889 USPAT2
 TI Dental/medical compositions comprising degradable polymers and methods
 of manufacture thereof
 IN Jia, Weitao, Wallingford, CT, United States
 Jin, Shuhua, Wallingford, CT, United States
 PA Pentron Corporation, Wallingford, CT, United States (U.S. corporation)
 PI US 6787584 B2 20040907
 AI US 2001-5298 20011205 (10)
 RLI Continuation-in-part of Ser. No. US 2000-368206, filed on 11 Aug 2000
 PRAI US 2000-251408P 20001205 (60)
 DT Utility
 FS GRANTED
 LN.CNT 838
 INCL INCLM: 523/115.000
 INCLS: 523/116.000; 523/117.000; 106/035.000; 433/228.100; 525/900.000;
 524/127.000; 528/354.000

NCL NCLM: 523/115.000
NCLS: 106/035.000; 433/228.100; 523/116.000; 523/117.000; 524/127.000;
528/354.000
IC [7]
ICM A61K006-08
ICS A61K006-087; A61C005-04
IPCI A61F0002-00 [ICM, 7]; C08K0003-00 [ICS, 7]
IPCI-2 A61K0006-08 [ICM, 7]; A61K0006-087 [ICS, 7]; A61K0006-02
[ICS, 7, C*]; A61C0005-04 [ICS, 7]
IPCR A61K0006-00 [I, C*]; A61K0006-00 [I, A]; A61K0006-02 [I, C*];
A61K0006-083 [I, A]; A61L0024-00 [I, C*]; A61L0024-04 [I, A];
A61L0027-00 [I, C*]; A61L0027-44 [I, A]; A61L0027-46 [I, A]
EXF 523/115; 523/116; 523/117; 106/35; 433/228.1; 525/300; 528/354; 524/127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 74 OF 77 USPAT2 on STN

Full Text

AN 2002:61564 USPAT2
TI Osteogenic implants derived from bone
IN Boyce, Todd M., Aberdeen, NJ, United States
Kaes, David, Toms River, NJ, United States
Scarborough, Nelson L., Ocean, NJ, United States
PA Osteotech, Inc., Eatontown, NJ, United States (U.S. corporation)
PI US 6808585 B2 20041026
AI US 2001-973597 20011009 (9)
RLI Division of Ser. No. US 2000-610026, filed on 3 Jul 2000
DT Utility
FS GRANTED
LN.CNT 1234
INCL INCLM: 156/244.110
INCLS: 156/245.000; 156/296.000; 264/109.000; 623/023.610; 623/023.630;
435/372.000
NCL NCLM: 156/244.110; 623/023.510
NCLS: 156/245.000; 156/296.000; 264/109.000; 435/372.000; 623/023.610;
623/023.630; 264/175.000; 264/211.000; 264/211.110; 264/236.000;
264/320.000; 264/322.000
IC [7]
ICM A61F002-28
IPCI A61F0002-28 [ICM, 7]; B29C0047-00 [ICS, 7]; B29C0043-02 [ICS, 7];
B29C0043-24 [ICS, 7]; B29C0043-52 [ICS, 7]
IPCI-2 A61F0002-28 [ICM, 7]
IPCR A61L0027-00 [I, A]; A61F0002-28 [I, C*]; A61F0002-28 [I, A];
A61L0027-00 [I, C*]; A61L0027-36 [I, A]
EXF 156/244.11; 156/245; 156/296; 623/23.61; 623/23.63; 523/113; 523/115;
435/372; 264/109

L16 ANSWER 75 OF 77 USPAT2 on STN

Full Text

AN 2001:165452 USPAT2
TI Compositions and methods for repair of osseous defects and accelerated
wound healing
IN Yang, Shih-Liang S., Laguna Hills, CA, United States
PA Unicare Biomedical, Inc., Laguna Hills, CA, United States (U.S.
corporation)
PI US 6482427 B2 20021119
AI US 2001-814481 20010315 (9)
RLI Continuation-in-part of Ser. No. US 1999-298683, filed on 23 Apr 1999,
now patented, Pat. No. US 6228386
DT Utility
FS GRANTED
LN.CNT 928
INCL INCLM: 424/426.000
INCLS: 523/114.000; 523/115.000
NCL NCLM: 424/426.000; 424/489.000
NCLS: 523/114.000; 523/115.000; 424/618.000
IC [7]
ICM A61F002-28
IPCI A61K0009-14 [ICM, 7]; A61K0033-38 [ICS, 7]
IPCI-2 A61F0002-28 [ICM, 7]
IPCR A61F0002-00 [N, A]; A61F0002-00 [N, C*]; A61F0002-28 [N, A];
A61F0002-28 [N, C*]; A61L0024-00 [I, C*]; A61L0024-02 [I, A];
A61L0027-00 [I, C*]; A61L0027-10 [I, A]; C03C0003-076 [I, C*];

C03C0003-097 [I,A]; C03C0004-00 [I,A]; C03C0004-00 [I,C*];
C03C0012-00 [I,A]; C03C0012-00 [I,C*]

EXF 424/426; 523/114; 523/115; 623/16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 76 OF 77 USPAT2 on STN

Full Text

AN 2001:154550 USPAT2
TI Preparation of polymer foam having gelled sol coating for intervertebral disc reformation
IN Gan, Jean Chin Chin, Ardmore, PA, United States
Ducheyne, Paul, Rosemont, PA, United States
Vresilovic, Edward, Philadelphia, PA, United States
Shapiro, Irving, Philadelphia, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 6569442 B2 20030527
AI US 2001-833284 20010412 (9)
RLI Division of Ser. No. US 1999-314511, filed on 19 May 1999, now patented, Pat. No. US 6240926 Division of Ser. No. US 1996-694191, filed on 8 Aug 1996, now patented, Pat. No. US 5964807
DT Utility
FS GRANTED
LN.CNT 742
INCL INCLM: 424/426.000
INCLS: 128/898.000; 424/423.000; 424/093.700; 435/176.000; 435/177.000;
435/180.000; 435/325.000; 435/381.000; 435/395.000; 435/397.000;
623/017.160
NCL NCLM: 424/426.000; 128/898.000
NCLS: 128/898.000; 424/093.700; 424/423.000; 435/176.000; 435/177.000;
435/180.000; 435/325.000; 435/381.000; 435/395.000; 435/397.000;
623/017.160; 427/002.100; 427/002.240; 427/002.270; 623/919.000
IC [7]
ICM A61F002-44
ICS A01N063-02; C12N011-14; C12N011-08; C12N005-08
IPCI A61F0002-28 [ICM,7]; A61B0019-00 [ICS,7]; A61F0002-44 [ICS,7]
IPCI-2 A61F0002-44 [ICM,7]; A01N0063-02 [ICS,7]; C12N0011-14 [ICS,7];
C12N0011-08 [ICS,7]; C12N0011-00 [ICS,7,C*]; C12N0005-08 [ICS,7]
IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-02 [N,A];
A61F0002-02 [N,C*]; A61F0002-30 [N,A]; A61F0002-30 [N,C*];
A61F0002-44 [I,A]; A61F0002-44 [I,C*]; A61L0027-00 [I,C*];
A61L0027-02 [I,A]; A61L0027-18 [I,A]; A61L0027-30 [I,A];
A61L0027-38 [I,A]; A61L0027-44 [I,A]; A61L0027-56 [I,A]
EXF 435/174; 435/176; 435/177; 435/180; 435/325; 435/378; 435/381; 435/395;
435/397; 424/93.7; 424/423; 424/426; 128/898; 623/17.16

L16 ANSWER 77 OF 77 USPAT2 on STN

Full Text

AN 2001:139311 USPAT2
TI Relic process for producing bioresorbable ceramic tissue scaffolds
IN Janas, Victor F., Monroe Township, NJ, United States
TenHuisen, Kevor Shane, Clinton, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 6667049 B2 20031223
AI US 2001-819214 20010328 (9)
RLI Division of Ser. No. US 1999-333231, filed on 14 Jun 1999
DT Utility
FS GRANTED
LN.CNT 499
INCL INCLM: 424/423.000
INCLS: 424/093.700; 435/176.000; 435/395.000; 435/399.000; 435/283.100;
435/284.100
NCL NCLM: 424/423.000; 435/395.000
NCLS: 424/093.700; 435/176.000; 435/283.100; 435/284.100; 435/395.000;
435/399.000; 264/610.000
IC [7]
ICM A61F002-00
ICS C12N005-06; C12N005-08; C12N003-00
IPCI C12N0005-08 [ICM,7]; C12N0005-06 [ICS,7]; B28B0001-00 [ICS,7]
IPCI-2 A61F0002-00 [ICM,7]; C12N0011-14 [ICS,7]; C12N0011-00 [ICS,7,C*];
C12N0005-06 [ICS,7]; C12N0005-08 [ICS,7]; C12N0003-00 [ICS,7]
IPCR A61F0002-00 [N,A]; A61F0002-00 [N,C*]; A61F0002-02 [N,A];

A61F0002-02 [N,C*]; A61F0002-28 [I,A]; A61F0002-28 [I,C*];
A61F0002-30 [I,A]; A61F0002-30 [I,C*]; A61F0002-44 [N,A];
A61F0002-44 [N,C*]; A61F0002-46 [N,A]; A61F0002-46 [N,C*];
A61L0027-00 [I,C*]; A61L0027-12 [I,A]

EXF 435/176; 435/180; 435/395; 435/399; 435/283.1; 435/284.1; 424/423;
424/93.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 116 an ti in pa pi ab kwic 55 59 65

L16 ANSWER 55 OF 77 USPATFULL on STN

Full Text

AN 2000:1556 USPATFULL
TI Bioactive sol-gel compositions and methods
IN Zhong, Jipin, Gainesville, FL, United States
Greenspan, David C., Gainesville, FL, United States
PA USBiomaterials Corp., Alachua, FL, United States (U.S. corporation)
PI US 6010713 20000104
AB A process for making bioactive glasses is described including preparing a reaction mixture of reactants capable of forming a sol-gel, aging the reaction mixture, near equilibrium drying a gel resulting from the reaction mixture, and heating the near equilibrium-dried gel described. Also described are near equilibrium-dried **bioactive glass** compositions.
AB . . . drying a gel resulting from the reaction mixture, and heating the near equilibrium-dried gel described. Also described are near equilibrium-dried **bioactive glass** compositions.
SUMM The present invention relates to **bioactive glass** compositions, for example, used for filling bone defects, and bioactive compositions produced by a sol-gel process. The present invention also. . .
SUMM Sol-gel processes for making **bioactive glass** using sol-gel technology are generally known. For example, U.S. Pat. No. 5,074,916 (the "'916 patent"), the subject matter of which is incorporated herein by reference, discloses sol-gel processing techniques used to produce alkali-free **bioactive glass** compositions based on SiO_2 , CaO and P_2O_5 . The '916 patent discloses that by varying the SiO_2 content, a range. . . during drying. U.S. Pat. No. 4,849,378 ("the 378 patent"), incorporated herein by reference discloses a method of fabricating an ultraporous **silicon dioxide** containing gel monolith having a predetermined mean pore size by controlling temperature, duration and other conditions of aging. The '378. . .
SUMM . . . and the pore texture of the monolith was not mentioned. Moreover, this patent does not address the preparation of a **bioactive glass**.
SUMM . . . yield bioactive glasses used for bone grafting and filling osseous defects, having larger pore size at a given level of **silicon dioxide** in the final composition, faster HCA formation, better resorbability, and better homogeneity. It is further an object of the present. . .
SUMM . . . gel resulting from the reaction mixture, and heating the near equilibrium-dried gel. The present invention is also directed to dried **bioactive glass** compositions and monolithic bioactive compositions having improved resorbability. The present invention is further directed to materials suitable for bone grafting, repairing of **tissue** defects and other orthopedic uses.
DRWD FIG. 10 FTIR spectra of various sol-gel **bioactive glass** compositions. All have formed extensive HCA layers.
DRWD FIG. 11(A) FTIR spectra of sol-gel **bioactive glass** prepared by previous method A.
DRWD FIG. 11(B) FTIR spectra of sol-gel **bioactive glass** made in accordance with the present invention including a near equilibrium drying step. As seen in the spectra, more rapid. . .
DRWD FIG. 12 FTIR spectra of sol-gel **bioactive glass** monolith after 24 hours in SBF using near equilibrium drying.
DETD . . . drying step which provides for increased pore size and bioactivity in the final product. The present invention also includes sol-gel **bioactive glass** compositions. The present invention further relates to materials suitable for bone grafting and repairing of **tissue** defects where the rate of resorption can be precisely controlled.
DETD As referred to herein, **bioactive glasses** are typically **silicon dioxide** based compositions capable of forming HCA when exposed to

physiological fluids. Typically, bioactive glasses have the following composition by weight.

DETD . . . the conditions near the two phase boundaries in the phase diagram at a temperature and pressure sufficient to yield a **bioactive glass** with large pore structure i.e. a pore structure sufficient to yield a **bioactive glass**. For example, near equilibrium drying may be drying under the conditions near the line in the phase diagram of water as shown in FIG. 17 (or other liquids such as methanol, ethanol, acetone, liquid CO₂, benzene and so on). By manipulating the sealing of the designed drying chamber to adjust the extent of the drying. . . of near-equilibrium drying, and the temperature at which the drying is conducted, one can drastically alter pore size of resultant **bioactive glass**. For example, increasing the sealing of the drying chamber during drying typically results in an increase in relative humidity and.

DETD . . . drying, and the temperature at which near equilibrium drying is conducted, one can drastically alter pore size of the resultant **bioactive glass**. For example, increasing the level of humidity during drying typically results in an increase in pore diameter. Near equilibrium drying.

DETD . . . in accordance with the present invention is any process that includes the use of a sol-gel in the preparation of **bioactive glass**. For example, a reaction mixture including tetraethoxysilane (TEOS), triethylphosphate (TEP), and calcium nitrate can be used to make sol-gel bioactive.

DETD . . . yields larger pore size in the final product and permits development of HCA very rapidly for both high and low **silicon dioxide** content gels. Indeed, compositions in accordance with the present invention form HCA more rapidly than prior gels when exposed to . . . homogeneity and physical structure. For example, previous sol-gel compositions were not able to provide adequate resorbability at higher levels of **silicon dioxide**. Surprisingly, the present invention provides for excellent resorbability even when high amounts of **silicon dioxide** are included. The sol-gel glasses of the present invention are also more homogeneous than prior sol-gel glasses and calcium is. . .

DETD The process of the present invention also provides for **bioactive glass** capable of resorbing more quickly than known sol-gel **bioactive glass** materials. For example, in-vivo testing of one embodiment of the present invention showed that more than 50% of sol-gel material . . . same extent, have not resorbed at all by eight weeks. Indeed, the '916 patent indicates glasses including more than 55% **silicon dioxide** are not bioactive. Moreover, **bioactive glass** made by the process of the present invention also exhibits substantially no unwanted inflammatory response.

DETD The preparation of sol-gel **bioactive glass** frit was accomplished as follows:

DETD . . . more dramatic results can be seen in FIGS. 4 and 5 which show extensive resorption in 60% by weight silica **bioactive glass** compositions after only 4 weeks in in vivo and very advanced resorption after only 8 weeks. This animal model included.

DETD 0.2 g of sol-gel **bioactive glass** particles of samples 77S(A) [no near equilibrium drying] and 77S(B) [equilibrium dried] were tested in 200 ml of SBF in. . .

CLM What is claimed is:

. . . method for treating orthopedic defects comprising contacting an orthopedic defect with a defect healing amount of near equilibrium dried sol-gel **bioactive glass**.

L16 ANSWER 59 OF 77 USPATFULL on STN

Full Text

AN 1999:24327 USPATFULL

TI Bioactive-gel compositions and methods

IN Zhong, Jipin, Gainesville, FL, United States

Greenspan, David C., Gainesville, FL, United States

PA US Biomaterials Corp., Alachua, FL, United States (U.S. corporation)

PI US 5874101 19990223

AB A process for making bioactive glasses is described including preparing a reaction mixture of reactants capable of forming a sol-gel, aging the reaction mixture, near equilibrium drying a gel resulting from the reaction mixture, and heating the -near equilibrium-dried gel described. Also described are near equilibrium-dried **bioactive glass** compositions.

AB . . . drying a gel resulting from the reaction mixture, and heating the -near equilibrium-dried gel described. Also described are near equilibrium-dried **bioactive glass** compositions.

SUMM The present invention relates to **bioactive glass** compositions, for example, used for filling bone defects, and **bioactive** compositions produced by a sol-gel process. The present invention also . . .

SUMM Sol-gel processes for making **bioactive glass** using sol-gel technology are generally known. For example, U.S. Pat. No. 5,074,916 (the "'916 patent"), the subject matter of which is incorporated herein by reference, discloses sol-gel processing techniques used to produce alkali-free **bioactive glass** compositions based on SiO_2 , CaO and P_2O_5 . The '916 patent discloses that by varying the SiO_2 content, a range. . .

SUMM . . . during drying. U.S. Pat. No. 4,849,378 ("the 378 patent"), incorporated herein by reference discloses a method of fabricating an ultraporous **silicon dioxide** containing gel monolith having a predetermined mean pore size by controlling temperature, duration and other conditions of aging. The '378. . .

SUMM . . . and the pore texture of the monolith was not mentioned. Moreover, this patent does not address the preparation of a **bioactive glass**.

SUMM . . . yield **bioactive glasses** used for bone grafting and filling osseous defects, having larger pore size at a given level of **silicon dioxide** in the final composition, faster HCA formation, better resorbability, and better homogeneity. It is further an object of the present. . .

SUMM . . . gel resulting from the reaction mixture, and heating the near equilibrium-dried gel. The present invention is also directed to dried **bioactive glass** compositions and monolithic **bioactive** compositions having improved resorbability. The present invention is further directed to materials suitable for bone grafting, repairing of **tissue** defects and other orthopedic uses.

DRWD FIG. 10 FTIR spectra of various sol-gel **bioactive glass** compositions. All have formed extensive HCA layers.

DRWD FIG. 11(A) FTIR spectra of sol-gel **bioactive glass** prepared by previous method A.

DRWD FIG. 11(B) FTIR spectra of sol-gel **bioactive glass** made in accordance with the present invention including a near equilibrium drying step. As seen in the spectra, more rapid. . .

DRWD FIG. 12 FTIR spectra of sol-gel **bioactive glass** monolith after 24 hours in SBF using near equilibrium drying.

DETD . . . drying step which provides for increased pore size and bioactivity in the final product. The present invention also includes sol-gel **bioactive glass** compositions. The present invention further relates to materials suitable for bone grafting and repairing of **tissue** defects where the rate of resorption can be precisely controlled.

DETD As referred to herein, **bioactive glasses** are typically **silicon dioxide** based compositions capable of forming HCA when exposed to physiological fluids. Typically, **bioactive glasses** have the following composition by weight. . .

DETD . . . the conditions near the two phase boundaries in the phase diagram at a temperature and pressure sufficient to yield a **bioactive glass** with large pore structure i.e. a pore structure sufficient to yield a **bioactive glass**. For example, near equilibrium drying may be drying under the conditions near the line in the phase diagram of water as shown in FIG. 17 (or other liquids such as methanol, ethanol, acetone, liquid CO_2 , benzene and so on). By manipulating the sealing of the designed drying chamber to adjust the extent of the drying. . . of near-equilibrium drying, and the temperature at which the drying is conducted, one can drastically alter pore size of resultant **bioactive glass**. For example, increasing the sealing of the drying chamber during drying typically results in an increase in relative humidity and. . .

DETD . . . drying, and the temperature at which near equilibrium drying is conducted, one can drastically alter pore size of the resultant **bioactive glass**. For example, increasing the level of humidity during drying typically results in an increase in pore diameter. Near equilibrium drying.

DETD . . . in accordance with the present invention is any process that includes the use of a sol-gel in the preparation of **bioactive glass**. For example, a reaction mixture including tetraethoxysilane (TEOS), triethylphosphate (TEP), and calcium nitrate can be used to make sol-gel

bioactive.

DETD . . . yields larger pore size in the final product and permits development of HCA very rapidly for both high and low silicon dioxide content gels. Indeed, compositions in accordance with the present invention form HCA more rapidly than prior gels when exposed to . . . homogeneity and physical structure. For example, previous sol-gel compositions were not able to provide adequate resorbability at higher levels of silicon dioxide. Surprisingly, the present invention provides for excellent resorbability even when high amounts of silicon dioxide are included. The sol-gel glasses of the present invention are also more homogeneous than prior sol-gel glasses and calcium is. . .

DETD The process of the present invention also provides for bioactive glass capable of resorbing more quickly than known sol-gel bioactive glass materials. For example, in-vivo testing of one embodiment of the present invention showed that more than 50% of sol-gel material . . . same extent, have not resorbed at all by eight weeks. Indeed, the '916 patent indicates glasses including more than 55% silicon dioxide are not bioactive. Moreover, bioactive glass made by the process of the present invention also exhibits substantially no unwanted inflammatory response.

DETD The preparation of sol-gel bioactive glass frit was accomplished as follows:

DETD . . . more dramatic results can be seen in FIGS. 4 and 5 which show extensive resorption in 60% by weight silica bioactive glass compositions after only 4 weeks in vivo and very advanced resorption after only 8 weeks. This animal model included. . .

DETD Other resorbability testing was also conducted on the foregoing comparative sol-gels. 0.2 g of sol-gel bioactive glass particles of samples 77S(A) [no near equilibrium drying] and 77S(B) [equilibrium dried] were tested in 200 ml of SBF in. . .

CLM What is claimed is:

18. A sol-gel process for making a bioactive glass monolith comprising: preparing a reaction mixture capable of forming a bioactive sol-gel monolith; casting the reaction mixture into a mold. . .

27. The composition of claim 23, wherein said glass further comprises at least 77% silicon dioxide.

L16 ANSWER 65 OF 77 USPATFULL on STN

Full Text

AN 97:58999 USPATFULL

TI Composite materials using bone bioactive glass and ceramic fibers

IN Marcolongo, Michele S., Lansdowne, PA, United States

Ducheyne, Paul, Rosemont, PA, United States

PA Trustees Of The University Of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

PI US 5645934 19970708

AB Composite materials formed from bone bioactive glass or ceramic fibers and structural fibers are disclosed. In preferred embodiments, a braid or mesh of interwoven bone bioactive glass or ceramic fibers and structural fibers is impregnated with a polymeric material to provide a composite of suitable biocompatibility and structural integrity. Most preferably, the mesh or braid is designed so that the bioactive fibers are concentrated at the surface of the implant to create a surface comprised of at least 30% bioactive material, thereby providing enhanced bone ingrowth. The interweaving between the bone bioactive glass or ceramic fibers and the core of structural fibers overcomes the problems found in prior composite systems where the bioactive material delaminates from the polymer. Preferred bioactive materials include calcium phosphate ceramics and preferred structural fibers include carbon fibers. Further preferred bioactive materials include aluminum oxide at greater than 0.2%, by mole. Improved prosthetic implants and methods of affixing an implant are thus also disclosed.

TI Composite materials using bone bioactive glass and ceramic fibers

AB Composite materials formed from bone bioactive glass or ceramic fibers and structural fibers are disclosed. In preferred embodiments, a braid or mesh of interwoven bone bioactive glass or ceramic fibers and structural fibers is impregnated with a polymeric material to provide a composite of suitable biocompatibility and. . . create a surface comprised of at least 30% bioactive material, thereby providing enhanced bone ingrowth. The interweaving between the bone bioactive

glass or ceramic fibers and the core of structural fibers overcomes the problems found in prior composite systems where the bioactive polymer. Preferred bioactive materials include calcium phosphate ceramics and preferred structural fibers include carbon fibers. Further preferred bioactive materials include aluminum oxide at greater than 0.2%, by mole. Improved prosthetic implants and methods of affixing an implant are thus also disclosed.

SUMM The present invention relates to composites made from fibers comprised of **bioactive glass** and the use of such composites to form implantable surfaces. In particular, the present invention relates to composites comprised of bone **bioactive glass** or ceramic fibers intermingled with structural fibers such as carbon fibers in a matrix of a polymeric material.

SUMM . . . have been employed as femoral components of hip implants to reduce stress shielding of the bone and consequently reduce bone **tissue** resorption. Currently, composite implants are stabilized in their bony bed by a press fit. With this method of stabilization, however, . . .

SUMM . . . bioactive coatings. Implants using porous polymer coatings seek to achieve fixation through mechanical interlocking between the implant and surrounding bone **tissue**, while the bioactive coatings are designed to attain fixation through a chemical bond between the implant and bone.

SUMM . . . Clin. Ortho. Rel. Res., 235:207-218 (1988). Although it is disclosed that some bone growth was evident, the majority of the **tissue** about the implant surface was fibrous. The porous polymer did not enhance the bone **tissue** growth in any way.

SUMM . . . Pat. No. 4,202,055--Reiner et al. The ceramic particles at the surface of this implant resorb and are replaced by bone **tissue**. There are no structural fibers and the polymer alone is intended to bear the load. This limits the load-bearing applications. . . . implantation. The calcium phosphate particles are added for strength and also resorb, therefore this device is not fixed to bone **tissue** through the chemical bonding of bioactive material or porous ingrowth.

SUMM . . . mineral fibers less than 20 millimeters long. This device is used as a grouting material to bond implants to bone **tissue**. The chopped fibers are not specifically tailored or designed for mechanical property optimization. A similar composition is disclosed in U.S.. . .

SUMM Much of the prior art discussed immediately above utilized calcium phosphate ceramic powders as the bioactive component of the composite. **Bioactive glass** materials were developed by Hench in 1969. See L. Hench, et al., "Bonding Mechanisms at the Interface of Ceramic Prosthetic Materials," J. Biomed. Mater. Res., 2:117-141 (1971). More recently, elongated, continuous **bioactive glass** fibers have been fabricated. See U. Pazzaglia, et al., "Study of the Osteoconductive Properties of **Bioactive Glass** Fibers," J. Biomed. Mater. Res., 23:1289-1297 (1989); and H. Tagai, et al., "Preparation of Apatite Glass Fiber for Application as Biomaterials," Ceramics in Surgery, Vincenzini, P. (Ed.), Amsterdam, Elsevier Sci. Pub. Co. (1983), p. 387-393. The latter reference discloses **bioactive glass** fibers in resorbable bone plates.

SUMM It has now been found that bone **bioactive glass** or ceramic fibers are useful as a chemical bonding vehicle in combination with a structural three-dimensional braided fiber substrate. The bioactive fibers enhance bone growth and bond to surrounding bone **tissue**. These bone **bioactive glass** or ceramic fibers are interwoven in the three dimensional braid with carbon fibers and infiltrated with a thermoplastic polymer to. . . .

DRWD FIG. 1 is an illustration of the apparatus used to draw bone **bioactive glass** or ceramic fibers used in the present invention.

DRWD FIG. 5 is a schematic illustrating the orientation and placement of fibers in a textile woven from bone **bioactive glass** or ceramic fibers and structural fibers in accordance with the present invention.

DETD . . . interface of the structural substrate and the carbon fiber/polymer interface, and to the interface between the bioactive surface and the **bioactive glass** fiber/polymer interface. As explained below, the bioactive section of the implant material is integrally incorporated into the substrate through a. . . .

DETD In the local environment of the **bioactive glass** fiber, a partial degradation occurs. As the **bioactive glass** fiber is resorbed it is replaced by bone **tissue**; the bone **tissue** is chemically bonded to the glass fiber and also interlocked with these fibers. Furthermore, the bioactivity reactions occurring at the glass surface lead to a

precipitation layer on the polymer. This layer, in turn, promotes bone tissue formation and bonding. The triple means of interfacial bonding leads to an interface which stabilizes the implant in its bony bed and provides stress transfer from the implant across the bonded interface into bone tissue. The bone is stressed, thus limiting bone tissue resorption due to stress shielding. This significant occurrence will increase the life of an implant because fixation and stability will not be lost due to bone tissue resorption, which is an initiator in the cascade of events leading to prosthesis loosening.

DETD In the present invention, a composition of bone bioactive glass or ceramic fibers is preferred. In the case of glass the preferred composition leads to a slowly reacting glass while. . . a large surface area of glass is exposed to physiological solutions during implantation with glass in a fibrous configuration. A bioactive glass that quickly degrades may lead to an adverse inflammatory response, impeding bone growth and bonding. The tradeoff is that since. . . too fluid, or the fibers would break upon drawing. Describing the compositional range for materials capable of being drawn into bioactive glass or ceramic fibers thus involves bioactivity versus manufacturability. A most preferred composition that can be successfully drawn into fibers while. . .

DETD The following Examples will discuss and explain the formation of a continuous fiber of a bioactive glass for use in a braided fiber and a woven fabric, both of which are impregnated with a polymeric material such. . .

DETD One bioactive glass fiber/polysulfone and one control polysulfone plug were implanted bilaterally in the medial proximal aspect of the tibia using aseptic techniques. . .

DETD . . . 400X. The composite material shows very close apposition to bone in areas of high fiber concentration. In these areas, bone bioactive glass or ceramic fibers are partially resorbed, more clearly seen in FIG. 3, taken at 1000X. In addition, in regions where. . . apposition is achieved, there is also bone apposition to the adjacent polysulfone matrix. In contrast, the polysulfone implants show bone tissue surrounding the plug, but with an interposing layer between the implant and bone tissue.

DETD Thus, the foregoing Example shows that the bioactive glass fiber/polysulfone plugs made in accordance with the present invention achieve a bond between surrounding bone tissue and the glass fibers at the implant surface. The bonded fibers are partially resorbed with bone tissue replacing the glass. Consequently, the method of glass fiber fixation to bone is not only by chemical bonding, but also by micromechanical interlocking. Additionally, there appears to be a bond between the adjacent polymer and surrounding bone tissue. This would lead to increased areas of fixation between the composite and bone beyond that of the fiber itself.

DETD . . . is formed, the polymer itself may act as a substrate for bone growth. Similar findings after implantation of a titanium fiber/bioactive glass composite in dogs were recently reported. Van Hove et al., *Bioceramics*, Vol. 6, P. Ducheyne and D. Christiansen, eds., pp. 319-325, Butterworth-Heinemann, Oxford (1993). This study shows bone growth over a titanium fiber which was between two islands of bioactive glass. If the separation between the glass was less than 50 microns, the titanium was covered with bone, but if it. . . coverage. An in vitro study has concluded that when a polymer is faced 1 mm or less away from a bioactive glass in simulated body fluid, a calcium phosphate layer is precipitated onto the polymer surface. See T. Kokubo, et al, "International. . .

DETD The histological observations of the foregoing Example indicate that bone bioactive glass or ceramic fibers in combination with polysulfone polymer will bond to bone tissue. This finding indicates that bone bioactive glass or ceramic fibers on the surface region of low modulus composite implants, such as hip stems and bone plates will. . .

DETD . . . composites with a bioactive powder dispersed through the polymer matrix. It has been determined having surface area partially covered by bioactive glass in a composite form leads to bone bonding in vivo. A calcium phosphate layer is the substrate for bone growth. . . of a calcium phosphate layer on a non-bioactive material is possible if the material is in close apposition to the bioactive glass. Consequently, it has been found that a composite with only a partial bioactive surface would still achieve bonding. Preferably, the. . .

DETD . . . impregnating the braid with a filler material, such as a polymer. In preferred embodiments of the present invention, continuous bone **bioactive glass** or ceramic fibers are grouped into 5000 filament fiber bundles. The fiber bundles (or "tow") are interwoven with carbon fibers into a braided textile preform. Most preferably, the bone **bioactive glass** or ceramic fibers are made in accordance with the composition formulation set forth above. As seen in FIG. 4, a. . . .

DETD . . . polymer fibers so as to achieve uniform polymer distribution throughout the fibrous preform. The final composite is machined to expose **bioactive glass** 100 fibers at the surface.

DETD . . . a carbon fiber, three dimensional structural reinforcement network. This results in a delamination resistant, interpenetrating fibrous network which allows bone **tissue** ingrowth.

DETD To facilitate composite processing, a thermoplastic matrix in filamentous form is co-mingled with the reinforcement fibers. As a result, the thermoplastic fibers are uniformly distributed through out the structure. A composite can. . . .

DETD In FIG. 5, the X's represent the bone **bioactive glass** or ceramic fibers, the number and distribution of which can vary, and the O's are a structural fiber, preferably carbon. . . .

DETD In a preferred embodiment, the integration of the bone **bioactive glass** or ceramic fibers into the carbon fiber in an interfacial region is accommodate by the position of the carrier in. . . .

DETD Thus, it will be appreciated that the present invention is very versatile in many of its parameters. The bone **bioactive glass** or ceramic fiber can be selected from **bioactive glass** or glass-ceramic materials, including calcium phosphate ceramic fibers. The polymer system used may be any polymer which bonds to the bone **bioactive glass** or ceramic fibers, is biocompatible, and does not inhibit the bioactivity of the fibers *in vivo*. Examples of such polymer. . . . In accordance with the present invention fibrous composites of biocompatible materials can be made into bioactive composites by incorporating bone **bioactive glass** or ceramic fibers into the weave at the bone contact surface.

DETD Classification of the *in vitro* reaction stages of the **bioactive glass** fibers according to the Hench system puts stages 1-3 in the first eight hours to 1 day. Stage 4 corresponds to 3 days immersion and Stage 5 is at 10 days immersion. A significant difference between 45S5 **bioactive glass** results and our own glass fibers is in the time differential. By 8 hours immersion, 45S5 **bioactive glass** had completed Stage 4 and was beginning Stage 5, which plateaus out to eleven days. In the **bioactive glass** fibers, Stage 5 or the formation of crystalline calcium phosphate did not occur at 3 days but was present at 10 days. Therefore, the **bioactive glass** fibers exhibited a reduced rate of surface reactivity, when compared to 45S5 **bioactive glass**.

DETD . . . diffraction (XRD) measurements using the Covina fibers were taken as 2θ varied from 10-150 using an automatic Rigaku diffractometer with Cu $\text{K}\alpha$. Data collection was performed with a receiving slit of 0.15 mm, a 2 scanspeed of 1/min and a 2. . . .

DETD . . . pp. 7-23, CRC Press, Boca Raton (1990); Kokubo et al., High Tech Ceramics, P. Vincenzini, ed., pp. 175-184, Elsevier, B. V., Amsterdam (1987); Kokubo et al., Materials in Medicine, 3:79-83 (1992); and Kokubo et al., Proceedings of XV International Congress of Glass, Vol. 3a, O. V. Mazurin, ed., pp. 114-119, Leningrad (1988)) primarily due to the increased network forming of the oxide. It has been hypothesized. . . .

DETD EXAMPLE V

DETD . . . retrieved sections of implant and bone were evaluated mechanically to quantify the interfacial bond strength; histologically, to observe the bone **tissue**/biomaterial interactions; and histomorphometrically, to quantify the amount of bone **tissue** present at the implant surface.

DETD . . . defect into which the plug was press-fit. Closure was in two stages: continuous sutures closure of the periosteum and soft **tissue** and continuous subcutaneous closure of the skin. The wounds were dressed and antibiotics were administered three days post-operatively. Radiographs were. . . .

DETD Interfacial bond strength values are shown in FIG. 8. The mean shear strength between the **bioactive glass** fiber/polymer composite and bone **tissue** after six weeks was 12.4 MPa (1798 psi), compared to the control polymer which had a mean value of 5.2. . . .

DETD . . . with CaCO_3 (50 g/L) and two parts 80% ethanol for a minimum of 24 hours. Following fixation, the blocks of tissue were consecutively dehydrated for 24 hours in each 70%, 80%, 90%, and 94% ethanol and for 48 hours in absolute. . .

DETD The composite material showed very close apposition to bone tissue at both three and six weeks. As seen in FIG. 9, by six weeks the bone tissue was well-integrated with the composite material. The bone was directly opposed to both fibers and polymer. The same observation was detected in FIG. 10 where the bone tissue was beginning to interact with the composite fibers after only three weeks. There were no distinct differences between the three. . .

DETD The interface between the polymer and bone was sometimes interposed by fibrous tissue, but often had spots of apparent bone contact. There was no interdigititation between the bone apposed to the polymer as. . .

DETD Scanning electron microscopy revealed bone tissue in direct apposition to bioactive glass fibers after six weeks of implantation. Morphologically, it appears as if a fiber in FIG. 11 is being incorporated into. . .

DETD The interface measured between the polymer region of composite material which was implanted for three weeks and bone tissue was approximately 3-4 μm thick. Calcium, phosphorous, sulfur, and silicon were detected in this layer by EDXA. Silicon was not. . .

DETD The areas where glass fibers were exposed to bone tissue revealed bone tissue adjacent to the glass fibers without an interposing fibrous tissue layer. A calcium-phosphate-rich reaction layer was detected on the surface of glass fibers which were in contact with bone tissue. However, a distinct region of a silica-rich layer was not detected through SEM/EDXA analysis. This may be due to the. . . layer may have been no thicker than the spatial resolution of the EDXA technique (approximately 2 μm). Previous studies of bioactive glass composite show silica-gel thickness layers to be one to two orders of magnitude greater than this (Van Hove et al.,. . . been hypothesized that a reduction in the thickness of the weak silica-gel layer will lead to increased bond strength between bioactive glass and bone (Van Hove et al., 1993, supra).

CLM What is claimed is:

1. A bioactive glass fiber comprising 40-60% SiO_2 , 10-21% CaO , up to about 6.3% P_2O_5 , at least 19% Na_2O , and greater than. . .

=> log y			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	97.23	187.11	

STN INTERNATIONAL LOGOFF AT 00:37:32 ON 14 APR 2007